Retractable (RVP) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 03, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'RETRACTABLE TECHNOLOGIES INC	'	'
Entity Central Index Key	'0000946563	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$19,581,725
Entity Common Stock, Shares Outstanding	'	27,296,312	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$27,629,359	$25,963,313
Accounts receivable, net of allowance for doubtful accounts of $1,698,506 and $2,186,190, respectively	3,476,718	3,694,307
Inventories, net	5,735,589	4,990,253
Income taxes receivable	'	9,431
Other current assets	1,065,641	783,760
Total current assets	37,907,307	35,441,064
Property, plant, and equipment, net	10,910,172	11,899,650
Intangible and other assets, net	279,965	291,444
Total assets	49,097,444	47,632,158
Current liabilities:	'	'
Accounts payable	5,107,778	5,099,884
Litigation proceeds subject to stipulation	7,724,826	'
Current portion of long-term debt	247,064	315,086
Accrued compensation	815,044	809,592
Dividends payable	57,613	57,613
Accrued royalties to shareholders	602,209	129,107
Other accrued liabilities	1,975,018	1,665,670
Income taxes payable	90,972	'
Total current liabilities	16,620,524	8,076,952
Long-term debt, net of current maturities	3,576,932	3,826,210
Total liabilities	20,197,456	11,903,162
Commitments and contingencies - See Note 8	'	'
Preferred Stock $1 par value:	'	'
Common Stock, no par value; authorized: 100,000,000 shares; outstanding: 27,187,702 and 27,252,463 shares, respectively	'	'
Additional paid-in capital	58,983,166	58,617,308
Retained deficit	-29,981,514	-23,767,662
Common stock in treasury - at cost; 722,920 and 67,102 shares, respectively	-1,096,609	-122,202
Total stockholders' equity	28,899,988	35,728,996
Total liabilities and stockholders' equity	49,097,444	47,632,158
Series I, Class B	'	'
Preferred Stock $1 par value:	'	'
Preferred stock	103,500	103,500
Series II, Class B	'	'
Preferred Stock $1 par value:	'	'
Preferred stock	178,700	178,700
Series III, Class B	'	'
Preferred Stock $1 par value:	'	'
Preferred stock	130,245	130,245
Series IV, Class B	'	'
Preferred Stock $1 par value:	'	'
Preferred stock	542,500	542,500
Series V, Class B	'	'
Preferred Stock $1 par value:	'	'
Preferred stock	$40,000	$46,607

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
BALANCE SHEETS	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$1,698,506	$2,186,190
Statement	'	'
Common stock, no par value (in dollars per share)	$0	$0
Common Stock, authorized shares	100,000,000	100,000,000
Common Stock, outstanding shares	27,187,702	27,252,463
Common stock in treasury - at cost; outstanding	722,920	67,102
Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, authorized shares	5,000,000	5,000,000
Series I, Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, outstanding shares	103,500	103,500
Preferred Stock, liquidation preference (in dollars)	646,875	646,875
Series II, Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, outstanding shares	178,700	178,700
Preferred Stock, liquidation preference (in dollars)	2,233,750	2,233,750
Series III, Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, outstanding shares	130,245	130,245
Preferred Stock, liquidation preference (in dollars)	1,628,063	1,628,063
Series IV, Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, outstanding shares	542,500	542,500
Preferred Stock, liquidation preference (in dollars)	5,967,500	5,967,500
Series V, Class B	'	'
Statement	'	'
Preferred stock, par value (in dollars per share)	$1	$1
Preferred Stock, outstanding shares	40,000	46,607
Preferred Stock, liquidation preference (in dollars)	$176,000	$205,071

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
STATEMENTS OF OPERATIONS	'	'	'
Sales, net	$30,785,127	$33,644,503	$32,102,296
Cost of Sales	'	'	'
Costs of manufactured product	18,000,408	19,776,198	18,556,257
Royalty expense to shareholders	2,474,762	2,691,887	2,643,209
Total cost of sales	20,475,170	22,468,085	21,199,466
Gross profit	10,309,957	11,176,418	10,902,830
Operating expenses:	'	'	'
Sales and marketing	4,414,339	4,220,809	3,439,535
Research and development	837,073	871,851	815,018
General and administrative	10,989,790	10,022,621	10,738,110
Total operating expenses	16,241,202	15,115,281	14,992,663
Loss from operations	-5,931,245	-3,938,863	-4,089,833
Interest and other income	38,943	46,999	62,596
Interest expense, net	-230,578	-231,210	-240,484
Litigation settlements, net	'	'	5,700,000
Income (loss) before income taxes	-6,122,880	-4,123,074	1,432,279
Provision for income taxes	90,972	9,818	13,797
Net income (loss)	-6,213,852	-4,132,892	1,418,482
Preferred Stock dividend requirements	-916,065	-918,108	-964,047
Earnings (loss) applicable to common shareholders	($7,129,917)	($5,051,000)	$454,435
Basic earnings (loss) per share (in dollars per share)	($0.26)	($0.19)	$0.02
Diluted earnings (loss) per share (in dollars per share)	($0.26)	($0.19)	$0.02
Weighted average common shares outstanding:	'	'	'
Basic (in shares)	26,999,698	26,219,728	24,171,238
Diluted (in shares)	26,999,698	26,219,728	26,354,786

STATEMENTS_OF_CHANGES_IN_STOCK

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)

Total

Series I Class B

Series II Class B

Series IV Class B

Series V Class B

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Additional Paid-in Capital

Retained Deficit

Treasury Stock

USD ($)

Series I Class B

Series II Class B

Series III Class B

Series IV Class B

Series V Class B

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Dec. 31, 2010

$38,900,501

'

'

'

'

$144,000

$219,700

$130,245

$552,500

$1,232,571

'

$57,674,737

($21,053,252)

'

Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

144,000

219,700

130,245

552,500

1,232,571

23,974,114

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exchange of Preferred Stock for Common Stock

'

'

'

'

'

-40,500

-41,000

'

-10,000

-1,185,964

'

1,277,464

'

'

Exchange of Preferred Stock for Common Stock (in shares)

1,277,464

40,500

41,000

10,000

1,185,964

-40,500

-41,000

'

-10,000

-1,185,964

1,277,464

'

'

'

Purchase of Preferred Stock

-1,357,275

'

'

'

'

'

'

'

'

'

'

-1,357,275

'

'

Recognition of stock option compensation

54,369

'

'

'

'

'

'

'

'

'

'

54,369

'

'

Recognition of stock option exercise (in shares)

'

'

'

'

'

'

'

'

'

'

67,122

'

'

'

Dividends

-364,625

'

'

'

'

'

'

'

'

'

'

-364,625

'

'

Net income (loss)

1,418,482

'

'

'

'

'

'

'

'

'

'

'

1,418,482

'

Balance at Dec. 31, 2011

38,651,452

'

'

'

'

103,500

178,700

130,245

542,500

46,607

'

57,284,670

-19,634,770

'

Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

103,500

178,700

130,245

542,500

46,607

25,318,700

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognition of stock option exercise

1,620,701

'

'

'

'

'

'

'

'

'

'

1,620,701

'

'

Recognition of stock option exercise (in shares)

'

'

'

'

'

'

'

'

'

'

2,000,865

'

'

'

Dividends

-288,063

'

'

'

'

'

'

'

'

'

'

-288,063

'

'

Repurchase of Common Stock

-122,202

'

'

'

'

'

'

'

'

'

'

'

'

-122,202

Repurchase of Common Stock (in shares)

'

'

'

'

'

'

'

'

'

'

-67,102

'

'

'

Net income (loss)

-4,132,892

'

'

'

'

'

'

'

'

'

'

'

-4,132,892

'

Balance at Dec. 31, 2012

35,728,996

'

'

'

'

103,500

178,700

130,245

542,500

46,607

'

58,617,308

-23,767,662

-122,202

Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

103,500

178,700

130,245

542,500

46,607

27,252,463

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Preferred Stock into Common Stock

'

'

'

'

'

'

'

'

'

-6,607

'

6,607

'

'

Conversion of Preferred Stock into Common Stock (in shares)

'

'

'

'

'

'

'

'

'

-6,607

6,607

'

'

'

Recognition of stock option compensation

52,775

'

'

'

'

'

'

'

'

'

'

52,775

'

'

Recognition of stock option exercise

536,925

'

'

'

'

'

'

'

'

'

'

536,925

'

'

Recognition of stock option exercise (in shares)

'

'

'

'

'

'

'

'

'

'

584,450

'

'

'

Dividends

-230,449

'

'

'

'

'

'

'

'

'

'

-230,449

'

'

Repurchase of Common Stock

-974,407

'

'

'

'

'

'

'

'

'

'

'

'

-974,407

Repurchase of Common Stock (in shares)

'

'

'

'

'

'

'

'

'

'

-655,818

'

'

'

Net income (loss)

-6,213,852

'

'

'

'

'

'

'

'

'

'

'

-6,213,852

'

Balance at Dec. 31, 2013

$28,899,988

'

'

'

'

$103,500

$178,700

$130,245

$542,500

$40,000

'

$58,983,166

($29,981,514)

($1,096,609)

Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

103,500

178,700

130,245

542,500

40,000

27,187,702

'

'

'

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income (loss)	($6,213,852)	($4,132,892)	$1,418,482
Adjustments to reconcile net income (loss) to net cash provided by (used by) operating activities:	'	'	'
Depreciation and amortization	1,284,249	1,335,858	1,311,746
Share based compensation	52,775	'	'
Provision for doubtful accounts	50,000	107,246	1,298,044
Provision for inventory valuation	530,000	120,000	52,835
Gain on disposal of assets	-1,000	'	'
Accreted interest	'	3,773	17,610
(Increase) decrease in assets:	'	'	'
Inventories	-1,275,336	1,127,166	2,391,937
Accounts receivable	167,589	-66,867	1,305,379
Income taxes receivable	9,431	30,054	-27,454
Other current assets	-281,881	-565,231	462,715
Increase (decrease) in liabilities:	'	'	'
Accounts payable	7,895	1,441,308	1,054,563
Litigation proceeds subject to stipulation	7,724,826	'	'
Other accrued liabilities	787,902	787,393	-3,646,555
Income taxes payable	90,971	-29,471	-125,529
Net cash provided by operating activities	2,933,569	158,337	5,513,773
Cash flows from investing activities:	'	'	'
Purchase of property, plant, and equipment	-283,289	-510,117	-826,091
Proceeds from sale of assets	1,000	'	'
Net cash used by investing activities	-282,289	-510,117	-826,091
Cash flows from financing activities:	'	'	'
Repayments of long-term debt and notes payable	-317,303	-626,219	-612,927
Repurchase of Preferred Stock	'	'	-1,357,275
Proceeds from the exercise of stock options	536,925	1,620,701	54,369
Repurchase of Common Stock	-974,407	-122,202	'
Payment of Preferred Stock dividends	-230,449	-230,450	-364,625
Net cash provided (used) by financing activities	-985,234	641,830	-2,280,458
Net increase in cash and cash equivalents	1,666,046	290,050	2,407,224
Cash and cash equivalents at:	'	'	'
Beginning of period	25,963,313	25,673,263	23,266,039
End of period	27,629,359	25,963,313	25,673,263
Supplemental schedule of cash flow information:	'	'	'
Interest paid	241,052	264,033	279,691
Income taxes paid	7,988	3,474	188,754
Supplemental schedule of noncash investing and financing activities:	'	'	'
Preferred dividends declared, not paid	57,613	57,613	'
Debt assumed for the purchase of molding machines	'	'	$534,986

BUSINESS_OF_THE_COMPANY_AND_BA

BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2013
BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION	'
BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION	'
	1	BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION
	Business of the Company
	Retractable Technologies, Inc. (the “Company”) was incorporated in Texas on May 9, 1994, and designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.  The Company began to develop its manufacturing operations in 1995.  The Company’s manufacturing and administrative facilities are located in Little Elm, Texas.  The Company’s primary products with Notice of Substantial Equivalence to the FDA are the VanishPoint® 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; the 0.5mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the allergy tray; the IV safety catheter; the Patient Safe® syringe; the Patient Safe® Luer Cap; and the VanishPoint® Blood Collection Set.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Accounting estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
	Cash and cash equivalents
	For purposes of reporting cash flows, cash and cash equivalents include unrestricted cash, the proceeds subject to a stipulation (discussed elsewhere herein), money market accounts, and investments with original maturities of three months or less.
	Accounts receivable
	The Company records trade receivables when revenue is recognized.  No product has been consigned to customers.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  This provision is reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.
	The Company requires certain customers to make a prepayment prior to beginning production or shipment of their order.  Customers may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in Other accrued liabilities on the Balance Sheets and are shown in Note 6, Other Accrued Liabilities.
	The Company records an allowance for estimated returns as a reduction to Accounts receivable and Gross sales.  Historically, returns have been immaterial.
	Inventories
	Inventories are valued at the lower of cost or market, with cost being determined using actual average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off.
	Property, plant, and equipment
	Property, plant, and equipment are stated at cost.  Expenditures for maintenance and repairs are charged to operations as incurred.  Cost includes major expenditures for improvements and replacements which extend useful lives or increase capacity and interest cost associated with significant capital additions.  For the years ended December 31, 2013, 2012, and 2011, the Company capitalized interest of approximately $10,474; $36,596; and $57,000.  Gains or losses from property disposals are included in income.
	Depreciation and amortization are calculated using the straight-line method over the following useful lives:
	Production equipment		3 to 13 years
	Office furniture and equipment		3 to 10 years
	Buildings		39 years
	Building improvements		15 years
	Automobiles		7 years
	Long-lived assets
	The Company assesses the recoverability of long-lived assets using an assessment of the estimated undiscounted future cash flows related to such assets.  In the event that assets are found to be carried at amounts which are in excess of estimated gross future cash flows, the assets will be adjusted for impairment to a level commensurate with fair value determined using a discounted cash flow analysis of the underlying assets.
	The Company’s property, plant, and equipment primarily consist of buildings, land, assembly equipment for syringes, molding machines, molds, office equipment, furniture, and fixtures.
	Intangible assets
	Intangible assets are stated at cost and consist primarily of intellectual property which is amortized using the straight-line method over 17 years.
	Financial instruments
	The Company estimates the fair market value of financial instruments through the use of public market prices, quotes from financial institutions, and other available information.  Judgment is required in interpreting data to develop estimates of market value and, accordingly, amounts are not necessarily indicative of the amounts that could be realized in a current market exchange.  Short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on Management’s estimates, equals their recorded values.  The fair value of long-term liabilities, based on Management’s estimates, approximates their reported values.
	Concentration risks
	The Company’s financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable.  Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality.  The majority of accounts receivable are due from companies which are well-established entities.  As a consequence, Management considers any exposure from concentrations of credit risks to be limited.
	The following table reflects our significant customers in 2013, 2012, and 2011:
			Years Ended December 31,
			2013		2012		2011
	Number of significant customers		2		3		4
	Aggregate dollar amount of net sales to significant customers		$9.3 million		$13.7 million		$16.2 million
	Percentage of net sales to significant customers		30.20%		40.60%		50.60%
	Considering the current economic climate, the Company increased its allowance for doubtful accounts by approximately $50,000 this year.
	The Company manufactures syringes in Little Elm, Texas as well as utilizing manufacturers in China.  The Company purchases most of its product components from single suppliers, including needle adhesives and packaging materials.  There are multiple sources of these materials.  The Company obtained roughly 72.9% of its finished products in 2013 from Double Dove, a Chinese manufacturer.  Purchases from Double Dove aggregated 72.0% and 67.1% of finished products in 2012 and 2011, respectively.  In the event that the Company becomes unable to purchase such product from Double Dove, the Company would need to find an alternate manufacturer for its 0.5mL insulin syringe, its 2mL, 5mL, and 10mL syringes and its autodisable syringe and increase domestic production for 1mL and 3mL syringes.
	Revenue recognition
	Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment.  Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances.  Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products that the Company has not received tracking reports.  Rebates are recorded when issued and are applied against the customer’s receivable balance.  Distributors receive a rebate for the difference between the Wholesale Acquisition Cost and the appropriate contract price as reflected on a tracking report provided by the distributor to the Company. If product is sold by a distributor to an entity that has no contract, there is a standard rebate (lower than a contracted rebate) given to the distributor.  One of the purposes of the rebate is to encourage distributors to submit tracking reports to the Company. The provision for contractual pricing allowances is reviewed at the end of each quarter and adjusted for changes in levels of products for which there is no tracking report.  Additionally, if it becomes clear that tracking reports will not be provided by individual distributors, the provision is further adjusted.  The estimated contractual allowance is included in Accounts payable and deducted from revenues in the Statements of Operations.  Accounts payable included estimated contractual allowances for $3,611,692 and $3,036,564 for 2013 and 2012, respectively.  The terms and conditions of contractual pricing allowances are governed by contracts between the Company and its distributors.  Revenue for shipments directly to end-users is recognized when title and risk of ownership pass from the Company.  Any product shipped or distributed for evaluation purposes is expensed.
	Certain distributors have taken rebates to which they are not entitled, such as utilizing a rebate for products not purchased directly from the Company.  Major customers said they have ceased the practices resulting in claiming non-contractual rebates.  Rebates can only be claimed on purchases made directly from the Company. The Company has established a reserve for the collectability of these non-contractual rebate amounts.  The expense for the reserve is recorded in Operating expense, General and administrative.  The reserve for such non-contractual deductions is included in the allowance for doubtful accounts.  There has been no change to the reserve contractual rebates in the periods currently presented.
	The Company’s domestic return policy is set forth in its standard Distribution Agreement.  This policy provides that a customer may return incorrect shipments within 10 days following arrival at the distributor’s facility.  In all such cases the distributor must obtain an authorization code from the Company and affix the code to the returned product.  The Company will not accept returned goods without a returned goods authorization number.  The Company may refund the customer’s money or replace the product.
	The Company’s domestic return policy also provides that a customer may return product that is overstocked.  Overstocking returns are limited to two times in each 12-month period up to 1% of distributor’s total purchase of products for the prior 12-month period.  All product overstocks and returns are subject to inspection and acceptance by the Company.
	The Company’s international distribution agreements do not provide for any returns.
	Litigation proceeds and settlements
	Proceeds from litigation are recognized when realizable.  Generally, realization is not reasonably assured and expected until proceeds are collected; however, see Note 8, COMMITMENTS AND CONTINGENCIES, for a discussion of proceeds received from Becton Dickinson and Company (“BD”) pursuant to a stipulation in the patent infringement case Retractable Technologies, Inc. and Thomas Shaw v. Becton Dickinson and Company, Civil Action No. 2:07-cv-250, in the U.S. District Court for the Eastern District of Texas, Marshall Division.
	Pursuant to a settlement agreement among the Company, Abbott, and Hospira, Inc. (“Hospira”), Hospira delivered $6 million to the Company in the third quarter of 2010.  The Company reduced its litigation settlements by $144,000 attributable to an unpaid Abbott invoice.  Abbott also waived its rights to any Series IV Class B Preferred Stock dividends.  Additionally, the Company granted Hospira an exclusive one-year option to negotiate a licensing agreement for certain uses of the Patient Safe® syringe, which option expired unexercised in July 2011.  The Company has received the $8.0 million option payments.  The Company recognizes proceeds from litigation settlements, net of any associated royalty expense.
	Income taxes
	The Company evaluates tax positions taken or expected to be taken in a tax return for recognition in the financial statements based on whether it is “more-likely-than-not” that a tax position will be sustained based upon the technical merits of the position.  Measurement of the tax position is based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.
	The Company provides for deferred income taxes through utilizing an asset and liability approach for financial accounting and reporting based on the tax effects of differences between the financial statement and tax bases of assets and liabilities, based on enacted rates expected to be in effect when such differences reverse in future periods.  Deferred tax assets are periodically reviewed for realizability.  The Company utilized some of its net operating loss carry forwards in 2011 and 2013 and paid Alternative Minimum Tax on its taxable income.  The Company has established a valuation allowance for its net deferred tax asset as future taxable income cannot be reasonably assured.  Penalties and interest related to income tax are classified as General and administrative expense and Interest expense, respectively, in the Statements of Operations.
	Earnings per share
	The Company computes basic earnings per share (“EPS”) by dividing net earnings for the period (adjusted for any cumulative dividends for the period) by the weighted average number of common shares outstanding during the period.  Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect, if any, of the common stock deliverable pursuant to stock options or common stock issuable upon the conversion of convertible preferred stock and convertible debt.  The calculation of diluted EPS excluded 1,305,847 and 1,373,345 shares of Common Stock underlying issued and outstanding stock options at December 31, 2013 and 2012, respectively, as their effect was antidilutive.  The potential dilution, if any, is shown on the following schedule:
			Years Ended December 31,
			2013				2012				2011
	Net income (loss)	$		(6,213,852	)	$		(4,132,892	)	$		1,418,482
	Preferred dividend requirements		(916,065		)		(918,108		)		(964,047		)
	Effect of dilutive securities:
	Convertible debt interest and loan fees		—				—				(10,120		)
	Earnings (loss) applicable to common shareholders after assumed conversions	$		(7,129,917	)	$		(5,051,000	)	$		444,315
	Average common shares outstanding		26,999,698				26,219,728				24,171,238
	Dilutive stock equivalents from stock options		—				—				2,101,825
	Shares issuable upon conversion of convertible debt		—				—				81,723
	Average common and common equivalent shares outstanding - assuming dilution		26,999,698				26,219,728				26,354,786
	Basic earnings (loss) per share	$		(0.26	)	$		(0.19	)	$		0.02
	Diluted earnings (loss) per share	$		(0.26	)	$		(0.19	)	$		0.02
Shipping and handling costs
The Company classifies shipping and handling costs as part of Cost of sales in the Statements of Operations.
Research and development costs
Research and development costs are expensed as incurred.
Share-based compensation
The Company’s share-based payments are accounted for using the fair value method.  The Company records share-based compensation expense on a straight-line basis over the requisite service period.  The Company incurred $52,775 in General and administrative cost related to share-based compensation in 2013.  No other departments or years incurred share-based compensation costs.
All stock options are fully vested; therefore, all stock option expense has been fully recognized.
Recent Pronouncement
In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”).  ASU 2013-11 requires, unless certain conditions exists, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward.  ASU 2013-11 is effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted.  Retrospective application is also permitted.  The adoption of ASU 2013-11, effective with the reporting period beginning January 1, 2014, is not expected to have an impact on the Company’s financial statements.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
INVENTORIES	'
INVENTORIES	'
	3	INVENTORIES
	Inventories consist of the following:
			Year Ended December 31,
			2013			2012
	Raw materials		$	1,666,525		$	1,692,133
	Finished goods		4,750,459			3,537,872
			2013			2012
			6,416,984			5,230,005
	Inventory reserve		(681,395		)	(239,752		)
			$	5,735,589		$	4,990,253

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT, AND EQUIPMENT	'
PROPERTY, PLANT, AND EQUIPMENT	'
	4	PROPERTY, PLANT, AND EQUIPMENT
	Property, plant, and equipment consist of the following:
			December 31,
			2013			2012
	Land		$	261,893		$	261,893
	Buildings and building improvements		11,389,181			11,354,210
	Production equipment		15,602,709			15,612,807
	Office furniture and equipment		3,114,451			2,821,179
	Construction in progress		610,679			731,258
	Automobiles		102,321			102,321
			31,081,234			30,883,668
	Accumulated depreciation		(20,171,062		)	(18,984,018		)
			$	10,910,172		$	11,899,650
	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $1,272,770; $1,264,326; and $1,267,813, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS	'
INTANGIBLE ASSETS	'
	5	INTANGIBLE ASSETS
	Intangible assets consist of the following:
			December 31,
			2013			2012
	Intellectual property		$	494,399		$	494,399
	Accumulated amortization		(219,358		)	(207,879		)
			$	275,041		$	286,520
	In 1995, the Company entered into a license agreement with the Chief Executive Officer of the Company for the exclusive right to manufacture, market, and distribute products utilizing automated retraction technology, which agreement has been amended twice.  This technology is the subject of various patents and patent applications owned by such officer of the Company.  The initial licensing fee of $500,000 was amortized over 17 years.  The license agreement also provides for quarterly payments of a 5% royalty fee on gross sales.  The royalty fee expense is recognized in the period in which it is earned.  Royalty fees of $2,474,762; $2,691,887; and $2,643,209 are included in Cost of sales for the years ended December 31, 2013, 2012, and 2011, respectively.  Royalties payable under this agreement aggregated $602,209 and $129,107 at December 31, 2013 and 2012, respectively.  Gross sales upon which royalties are based were $49,495,232; $53,837,732; and $52,864,158 for 2013, 2012, and 2011, respectively.
	Amortization expense for the years ended December 31, 2013, 2012, and 2011, was $11,479; $71,532; and $43,934, respectively.  Future amortization expense for the years 2014 through 2018 is estimated to be $11,479 per year.

OTHER_ACCRUED_LIABILITIES

OTHER ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2013
OTHER ACCRUED LIABILITIES	'
OTHER ACCRUED LIABILITIES	'
	6	OTHER ACCRUED LIABILITIES
	Other accrued liabilities consist of the following:
			December 31,
			2013			2012
	Prepayments from customers	$		1,720,896	$		1,400,740
	Accrued professional fees		169,125			162,969
	Other accrued expenses		84,997			101,961
		$		1,975,018	$		1,665,670

LONGTERM_DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2013
LONG-TERM DEBT	'
LONG-TERM DEBT	'
	7	LONG-TERM DEBT
			December 31,
			2013			2012
	Long-term debt consists of the following:
	Loan from American First National Bank. It has a 20 year amortization and 10 year maturity from December 10, 2009. The loan provided funding for the expansion of the warehouse, additional office space, and a new Controlled Environment. The loan is secured by the Company’s land and buildings. The interest rate is 5.968%.		$	3,717,795		$	3,852,512
	Note payable to Deutsche Leasing USA, Inc. The interest rate is 5.57%. The original amount of the note was $327,726 with a 36 month maturity ending in April 2014. In May 2011, the loan became payable in equal installments of principal and interest of approximately $9,900. Collateralized by three molding machines. It has a purchase option of $1.00 at the end of the term.		39,169			152,415
	Note payable to Deutsche Leasing USA, Inc. The interest rate is 5.57%. The original amount of the note was $207,260 with a 36 month maturity ending in November 2014. Beginning December 2011, the loan became payable in equal installments of principal and interest of approximately $6,300. Collateralized by a molding machine. It has a purchase option of $1.00 at the end of the term.		67,032			136,369
			3,823,996			4,141,296
	Less: current portion		(247,064		)	(315,086		)
			$	3,576,932		$	3,826,210
	The fair value of long-term liabilities, based on Management’s estimates, approximates their reported values.
	The aggregate maturities of long-term debt as of December 31, 2013, are as follows:
	2014		$	247,064
	2015		149,742
	2016		159,182
	2017		169,211
	2018		179,868
	Thereafter		2,918,929
			$	3,823,996

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES	'
COMMITMENTS AND CONTINGENCIES	'
	8	COMMITMENTS AND CONTINGENCIES
	On May 19, 2010, final judgment was entered in the U.S. District Court for the Eastern District of Texas, Marshall Division for the Company which ordered that the Company recover $5,000,000 plus prejudgment and post-judgment interest, and ordered a permanent injunction for BD’s 1mL and 3mL Integra syringes until the expiration of certain patents.  The permanent injunction was stayed for the longer of the exhaustion of the appeal of the district court’s case or twelve months from May 19, 2010.  In June 2010, BD filed an appeal in the U.S. Court of Appeals for the Federal Circuit appealing the final judgment entered on May 19, 2010.  In July 2011, a three-judge panel of the U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment that BD’s 3mL Integra infringed the Company’s ‘224 patent and ‘077 patent.  The U.S. Court of Appeals for the Federal Circuit affirmed the district court’s judgment that the 1mL Integra infringes the Company’s ‘244 and ‘733 patents.  The U.S. Court of Appeals for the Federal Circuit also affirmed the district court’s judgment that the ‘077 patent is not invalid for anticipation or obviousness.  The Company had petitioned for a rehearing by all the judges of the Federal Circuit as to whether the three-judge panel properly construed the Company’s patent claim language in finding that the 3mL Integra did not infringe.  The Company’s petition for rehearing by all of the judges of the Federal Circuit was denied with two dissents being issued.  The Company filed a petition for certiorari asking the Supreme Court to review the matter.  That petition was denied in January of 2013.  On August 7, 2013, the U.S. District Court for the Eastern District of Texas issued an order adopting the Magistrate Judge’s Report and Recommendation and denying BD’s Rule 60 motion seeking a reduction in damages.  On October 29, 2013, BD filed its Notice of Appeal of the August 7, 2013 order to the Federal Circuit.  Oral argument for this appeal has been set for May 9, 2014.  On September 30, 2013, the Company received payment of $7,724,826 (the “Judgment Amount”) from BD pursuant to a stipulation in this case.  The stipulation provides that if, as a result of BD’s appeal of the District Court’s denial of BD’s Rule 60 motion, it is judicially determined that BD owes an amount less than the Judgment Amount, BD shall be entitled to restitution by the Company of any excess payment, with interest.  Otherwise, the payment of the Judgment Amount shall constitute satisfaction of the patent infringement judgment and BD shall owe no further money damages to the Company in this case.  The Judgment Amount has been reflected as a current liability in the Balance Sheets since the proceeds are not yet realizable.
	In May 2010, the Company and an officer’s suit against BD in the U.S. District Court for the Eastern District of Texas, Marshall Division alleging violations of antitrust acts, false advertising, product disparagement, tortious interference, and unfair competition was reopened.  The Company and an officer filed a Second Amended Complaint on July 23, 2010 setting forth additional detail regarding the allegations of BD’s illegal conduct.  BD filed a motion to dismiss and the U.S. District Court for the Eastern District of Texas, Marshall Division denied that motion in part and granted it in part, granting the Company the right to re-plead certain allegations by May 13, 2011.  The Company and an officer filed a Third Amended Complaint in May 2011, setting forth additional detail regarding the alleged illegal conduct by BD.  Trial was initially set for February 2012.  However, in January 2012 the parties agreed to a continuance to allow the petition for certiorari to be considered.  As stated above, the petition was denied in January of 2013.  A hearing to re-set a trial date in light of BD’s motion for continuance was held May 3, 2013.  The trial commenced on September 9, 2013 in Tyler, Texas, and the jury returned its verdict on September 19, 2013, finding that BD illegally engaged in anticompetitive conduct with the intent to acquire or maintain monopoly power in the safety syringe market and engaged in false advertising under the Lanham Act.  The jury awarded the Company $113,508,014 in damages for the antitrust claim, which is subject to being trebled pursuant to statute.  The Court conducted a hearing for post-trial motions on February 7, 2014.  An order has not yet issued.  BD has stated that it plans to appeal the verdict.
	In September 2007, BD and MDC Investment Holdings, Inc. (“MDC”) sued the Company in the United States District Court for the Eastern District of Texas, Texarkana Division, initially alleging that the Company is infringing two U.S. patents of MDC (6,179,812 and 7,090,656) that are licensed to BD. BD and MDC seek injunctive relief and unspecified damages.  The Company counterclaimed for declarations of non-infringement, invalidity, and unenforceability of the asserted patents.  The plaintiffs subsequently dropped allegations with regard to patent no. 7,090,656 and the Company subsequently dropped its counterclaims for unenforceability of the asserted patents.  The United States District Court for the Eastern District of Texas, Texarkana Division conducted a claims construction hearing on September 25, 2008 and issued its claims construction order on November 14, 2008.  The case has been stayed pending resolution of the Company’s first filed case against BD described above.  As of March 27, 2014, there has been no activity in this case since the stay.
	Operating Leases
	In 2010, the Company entered into a non-cancellable operating lease for additional office space.  Rent expense under this lease for the years ended December 31, 2013, 2012, and 2011 was $61,607; $60,401; and $59,195, respectively.  Future annual minimum rental payments as of December 31, 2013 are presented below:
	2014	$	62,813
	2015		59,966
	Total	$	122,779

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
INCOME TAXES	'
	9	INCOME TAXES
	The provision for income taxes consists of the following:
			For the Years Ended December 31,
			2013			2012			2011
	Current tax provision (benefit)
	Federal		$	83,470		$	1,785		$	(29,070	)
	State		7,502			8,033			42,867
	Total current provision (benefit)		90,972			9,818			13,797
	Deferred tax provision (benefit)
	Federal		—			—			—
	State		—			—			—
	Total deferred tax provision (benefit)		—			—			—
	Total income tax provision (benefit)		$	90,972		$	9,818		$	13,797
	The Company has $10,072,410 in tax benefits attributable to carry back losses for federal tax purposes.  The loss carry forwards will begin to expire in 2028 for federal tax purposes and began to expire for state tax purposes in 2013.
	Deferred taxes are provided for those items reported in different periods for income tax and financial reporting purposes.  The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below:
			December 31,
			2013			2012
	Deferred tax assets
	Net operating loss carry forwards	$	3,819,961	$		4,873,433
	Credit for alternative minimum tax paid		83,470			—
	Accrued expenses and reserves		1,350,125			1,165,658
	Employee stock option expense		315,711			295,696
	Inventory		338,253			319,830
	Non-employee stock option expense		—			15,546
	Litigation proceeds subject to stipulation		2,929,640			—
	Deferred tax assets		8,837,160			6,670,163
	Deferred tax liabilities
	Property and equipment		(393,343	)		(631,109	)
	Deferred tax liabilities		(393,343	)		(631,109	)
	Net deferred assets		8,443,817			6,039,054
	Valuation allowance		(8,443,817	)		(6,039,054	)
	Net deferred tax assets	$	—	$		—
	The valuation allowance increased $2,404,763 and $1,155,638 for 2013 and 2012, respectively.
	A reconciliation of income taxes based on the federal statutory rate and the provision (benefit) for income taxes is summarized as follows:
			December 31,
			2013		2012		2011
	Income tax (benefit) at the federal statutory rate		35	%	35	%	35	%
	State tax (benefit), net of federal (benefit)		2.9		2.9		2.9
	Decrease (increase) in valuation allowance		(39.3	)	(28.0	)	—
	Permanent differences		(0.3	)	1.2		2
	Return to accrual adjustments		—		—		(2.8	)
	Alternative minimum tax		(1.4	)	—		3.4
	Adjustments to temporary differences for stock options		—		(11.0	)	—
	Release of valuation allowance – Net operating loss carry forward		—		—		(39.0	)
	Other		1.6		(0.3	)	(0.5	)
	Effective tax (benefit) rate		(1.5	)%	(0.2	)%	1	%
	The Company files income tax returns in the U.S. federal jurisdiction and in various state and local jurisdictions.  The Company’s federal income tax returns for all tax years ended on or after December 31, 2010, remain subject to examination by the Internal Revenue Service.  The Company’s state and local income tax returns are subject to examination by the respective state and local authorities over various statutes of limitations, most ranging from three to five years from the date of filing.

EXCHANGE_OF_PREFERRED_STOCK_FO

EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH	12 Months Ended
	Dec. 31, 2013
EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH	'
EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH	'
	10	EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH
	On September 12, 2011, the Company commenced the 2011 Exchange Offer and also engaged in private purchases with three Preferred Stockholders.  As of December 31, 2011, Preferred Stockholders had tendered a total of 1,277,464 shares of Preferred Stock.  A total of $1,357,275 was paid and 1,277,464 shares of Common Stock were issued as consideration to these Preferred Stockholders.  These Preferred Stockholders agreed to waive all unpaid dividends in arrears associated with their tendered Preferred Stock, which resulted in a waiver of a total of $3,592,659 in unpaid dividends in arrears.
	The 2011 Exchange Offer and private sales are summarized in the table below.
			Number of	Cash Outlay		Number of	Accrued		Amount of
			Preferred	by Company		Common	Dividends		Annual
			Stock Shares			Stock Shares	Eliminated		Dividend
			Tendered by			Tendered by			Reduction
			Preferred			Company
			Stockholders
	Series I Class B Stock		40,500	$	60,750	40,500	$	—	$	20,250
	Series II Class B Stock		41,000	123,000		41,000	—		41,000
	Series IV Class B Stock		10,000	35,000		10,000	114,575		10,000
	Series V Class B Stock		1,185,964	1,138,525		1,185,964	3,478,084		379,508
	Total Class B Stock		1,277,464	$	1,357,275	1,277,464	$	3,592,659	$	450,758

STOCK_REPURCHASE_PROGRAM

STOCK REPURCHASE PROGRAM	12 Months Ended
	Dec. 31, 2013
STOCK REPURCHASE PROGRAM	'
STOCK REPURCHASE PROGRAM	'
	11	STOCK REPURCHASE PROGRAM
	On July 10, 2012, the Company authorized a Common Stock repurchase plan structured to comply with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934.  Under the plan, the Company purchased 655,818 and 67,102 shares in 2013 and 2012, respectively.  The plan was terminated effective August 30, 2013.
	Pursuant to the Certificates of Designation, Preferences, Rights And Limitations of the Series I Class B and Series II Class B Convertible Preferred Stock, the Company would have been prohibited from purchasing its Common Stock while dividends were in arrears.  Therefore, to facilitate the Common Stock repurchase plan, the Company paid dividends on the Series I Class B Preferred Stock in the amount of $38,813 on July 31, 2012 and in the amount of $12,938 at each date on October 22, 2012, January 21, 2013, April 22, 2013, and July 22, 2013.  The Company paid dividends to Series II Class B Preferred Stockholders in the amount of $134,025 on July 31, 2012 and in the amount of $44,675 on each of the same four dates listed in the preceding sentence.

STOCK_OPTION_GRANT

STOCK OPTION GRANT	12 Months Ended
	Dec. 31, 2013
STOCK OPTION GRANT	'
STOCK OPTION GRANT	'
	12	STOCK OPTION GRANT
	The Compensation and Benefits Committee approved a grant of a non-qualified stock option pursuant to the 2008 Stock Option Plan to Walter O. Bigby, Jr., a Director, for the purchase of 50,000 shares of Common Stock on May 14, 2013.  Related share based compensation of $52,775 is included in general and administrative expense in the accompanying Statements of Operations.

DIVIDENDS

DIVIDENDS	12 Months Ended
	Dec. 31, 2013
DIVIDENDS	'
DIVIDENDS	'
	13	DIVIDENDS
	On October 21, 2013 and December 20, 2013, the Board of Directors declared dividends on the Series I Class B Preferred Stock in the amount of $12,938 on each date which were paid on November 11, 2013 and January 20, 2014.  The Company also declared and paid dividends to Series II Class B Preferred Stockholders in the amount of $44,675 on the same dates.  See Note 11 for information about dividends paid during the term of the Stock Repurchase Program.

STOCK_OPTION_EXERCISES

STOCK OPTION EXERCISES	12 Months Ended
	Dec. 31, 2013
STOCK OPTION EXERCISES	'
STOCK OPTION EXERCISES	'
	14	STOCK OPTION EXERCISES
	On July 10, 2012, the Chief Executive Officer of the Company exercised a portion of his stock option.  The Company issued 2,000,000 shares of Common Stock to him at an exercise price of $0.81 (aggregate consideration of $1,620,000).
	Some employees exercised stock options at various dates in 2013 and, consequently, they were issued a total of 584,450 shares of Common Stock for an aggregate payment of $536,925 to exercise such options. These options were granted in 2008 and 2009 at exercise prices of $0.81 and $1.30.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
STOCKHOLDERS' EQUITY	'
STOCKHOLDERS' EQUITY	'
	15	STOCKHOLDERS’ EQUITY
	Preferred Stock
	The Company is authorized to issue 5,000,000 shares of Preferred Stock Class A with a par value of One Dollar ($1.00) per share; 5,000,000 shares of Preferred Stock Class B with a par value of One Dollar ($1.00) per share; and 5,000,000 shares of Preferred Stock Class C with a par value of One Dollar ($1.00) per share.
	The Company has one class of Preferred Stock outstanding: Class B Convertible Preferred Stock (“Class B Stock”).  The Class B Stock has five series: Series I, Series II, Series III, Series IV, and Series V.
	The Class B Stock has been allocated among Series I, II, III, IV, and V in the amounts of 103,500; 178,700; 130,245; 542,500; and 40,000 shares, respectively as of December 31, 2013.  The remaining 4,005,055 authorized shares have not been assigned a series.
	Series I Class B Stock
	There were 103,500 shares of $1 par value Series I Class B Stock outstanding at December 31, 2013 and 2012.  Holders of Series I Class B Stock are entitled to receive a cumulative annual dividend of $0.50 per share, payable quarterly if declared by the Board of Directors.  The Company paid dividends of $38,814, $51,751, and $90,000 in 2013, 2012, and 2011, respectively.  At December 31, 2013, approximately $13,000 of dividends which had not been declared were in arrears.  Such arrearage was paid on January 20, 2014.
	Series I Class B Stock is redeemable after three years from the date of issuance at the option of the Company at a price of $7.50 per share, plus all unpaid dividends.  Each share of Series I Class B Stock may, at the option of the stockholder, be converted to one share of Common Stock after three years from the date of issuance or in the event the Company files an initial registration statement under the Securities Act of 1933.  Pursuant to these terms, no shares of Series I Class B Stock were converted into Common Stock in 2013 or 2012.  In the event of voluntary or involuntary dissolution, liquidation, or winding up of the Company, holders of Series I Class B Stock then outstanding are entitled to $6.25 per share, plus all unpaid dividends prior to any distributions to holders of Series II Class B Stock, Series III Class B Stock, Series IV Class B Stock, Series V Class B Stock, or Common Stock.
	Series II Class B Stock
	There were 178,700 shares of $1 par value Series II Class B Stock outstanding at December 31, 2013 and 2012.  Holders of Series II Class B Stock are entitled to receive a cumulative annual dividend of $1.00 per share, payable quarterly if declared by the Board of Directors.  Holders of Series II Class B Stock generally have no voting rights until dividends are in arrears and unpaid for twelve consecutive quarters.  In such case, the holders of Series II Class B Stock have the right to elect one-third of the Board of Directors of the Company.  The Company paid dividends of $134,025, $178,700, and $274,625 in 2013, 2012, and 2011, respectively.  At December 31, 2013, approximately $45,000 of dividends which had not been declared were in arrears.  Such arrearage was paid on January 20, 2014.
	Series II Class B Stock is redeemable after three years from the date of issuance at the option of the Company at a price of $15.00 per share plus all unpaid dividends.  Each share of Series II Class B Stock may, at the option of the stockholder, be converted to one share of Common Stock after three years from the date of issuance or in the event the Company files an initial registration statement under the Securities Act of 1933.  Pursuant to these terms, no shares of Series II Class B Stock were converted into Common Stock in 2013 or 2012.  In the event of voluntary or involuntary dissolution, liquidation, or winding up of the Company, holders of Series II Class B Stock then outstanding are entitled to $12.50 per share, plus all unpaid dividends, after distribution obligations to holders of Series I Class B Stock have been satisfied and prior to any distributions to holders of Series III Class B Stock, Series IV Class B Stock, Series V Class B Stock, or Common Stock.
	Series III Class B Stock
	There were 130,245 shares of $1 par value Series III Class B Stock outstanding at December 31, 2013 and 2012.  Holders of Series III Class B Stock are entitled to receive a cumulative annual dividend of $1.00 per share, payable quarterly if declared by the Board of Directors.  At December 31, 2013 and 2012, approximately $3,627,000 and $3,497,000, respectively, of dividends which have not been declared were in arrears.
	Series III Class B Stock is redeemable after three years from the date of issuance at the option of the Company at a price of $15.00 per share, plus all unpaid dividends.  Each share of Series III Class B Stock may, at the option of the stockholder, be converted to one share of Common Stock after three years from the date of issuance or in the event the Company files an initial registration statement under the Securities Act of 1933.  Pursuant to these terms, no shares of Series III Class B Stock were converted into Common Stock in 2013 or 2012.  In the event of voluntary or involuntary dissolution, liquidation, or winding up of the Company, holders of Series III Class B Stock then outstanding are entitled to $12.50 per share, plus all unpaid dividends, after distribution obligations to Series I Class B Stock and Series II Class B Stock have been satisfied and prior to any distributions to holders of Series IV Class B Stock, Series V Class B Stock, or Common Stock.
	Series IV Class B Stock
	There were 542,500 shares of $1 par value Series IV Class B Stock outstanding at December 31, 2013 and 2012.  Holders of Series IV Class B Stock are entitled to receive a cumulative annual dividend of $1.00 per share, payable quarterly, if declared by the Board of Directors.  At December 31, 2013 and 2012, approximately $7,423,000 and $6,881,000, respectively, of dividends which have not been declared were in arrears.
	Series IV Class B Stock is redeemable after three years from the date of issuance at the option of the Company at a price of $11.00 per share plus all unpaid dividends.  Each share of Series IV Class B Stock may, at the option of the stockholder any time subsequent to three years from date of issuance, be converted into one share of Common Stock, or in the event the Company files an initial registration statement under the Securities Act of 1933.  Pursuant to these terms, no shares of Series IV Class B Stock were converted into Common Stock in 2013 or 2012.  In the event of voluntary or involuntary liquidation, dissolution, or winding up of the Company, holders of Series IV Class B Stock then outstanding are entitled to receive liquidating distributions of $11.00 per share, unpaid dividends after distribution obligations to Series I Class B Stock, Series II Class B Stock, and Series III Class B Stock have been satisfied and prior to any distribution to holders of Series V Class B Stock or Common Stock.
	Series V Class B Stock
	There were 40,000 and 46,607 shares of $1 par value Series V Class B Stock outstanding at December 31, 2013 and 2012, respectively.  Holders of Series V Class B Stock are entitled to receive a cumulative annual dividend of $0.32 per share, payable quarterly, if declared by the Board of Directors.  At December 31, 2013 and 2012, approximately $942,000 and $929,000, respectively, of dividends which have not been declared were in arrears.
	Series V Class B Stock is redeemable after two years from the date of issuance at the option of the Company at a price of $4.40 per share plus all unpaid dividends.  Each share of Series V Class B Stock may, at the option of the stockholder any time subsequent to the date of issuance, be converted into Common Stock.  Pursuant to these terms, 6,607 shares of Series IV Class B Stock were converted into Common Stock in 2013 and none were converted in 2012.  In the event of voluntary or involuntary liquidation, dissolution, or winding up of the Company, holders of Series V Class B Stock then outstanding are entitled to receive liquidating distributions of $4.40 per share, plus unpaid dividends after distribution obligations to Series I Class B Stock, Series II Class B Stock, Series III Class B Stock, and Series IV Class B Stock have been satisfied and prior to any distribution to the holders of the Common Stock.
	Common stock
	The Company is authorized to issue 100,000,000 shares of no par value Common Stock, of which 27,187,702 and 27,252,463 shares were outstanding at December 31, 2013 and 2012, respectively.  The Company had a Common Stock repurchase plan structured to comply with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934 until termination of such plan in August 2013.  Under the plan, the Company purchased 67,102 shares in 2012 and 655,818 shares in 2013.  Such purchased shares are recorded as treasury stock.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
RELATED PARTY TRANSACTIONS	'
RELATED PARTY TRANSACTIONS	'
	16	RELATED PARTY TRANSACTIONS
	The Company has a license agreement with the Chief Executive Officer of the Company. See Note 5.
	The Chief Executive Officer of the Company exercised a portion of his stock option in 2012.  See Note 14.
	During the years ended December 31, 2013, 2012, and 2011, the Company paid $93,939; $91,086; and $96,787, respectively, to a family member of its Chief Executive Officer as an employee and consultant.
	The Chief Executive Officer exchanged his Preferred Stock shares for Common Stock and cash in the fourth quarter of 2011 pursuant to the 2011 Exchange Offer on the same terms as were offered to all Preferred Stockholders.  He received 86,607 shares of Common Stock and $95,843 in exchange for 5,000 shares of Series IV Preferred Stock and 81,607 shares of Series V Preferred Stock, and he waived a total of $58,110 in unpaid dividends in arrears.  The Company’s Common Stock had a closing stock price of $1.39 at November 4, 2011, the expiration date of the 2011 Exchange Offer.

STOCK_OPTIONS

STOCK OPTIONS	12 Months Ended
	Dec. 31, 2013
STOCK OPTIONS	'
STOCK OPTIONS	'
	17	STOCK OPTIONS
	Stock options
	The Company has approved stock option plans for the granting of stock options to employees, Directors, and consultants.  Options for the purchase of 700 shares of Common Stock remain outstanding under the 1999 Stock Option Plan, which terminated pursuant to its terms in 2009.  Options for the purchase of 2,899,108 shares of Common Stock have been issued under the 2008 Stock Option Plan, which authorized a total of 3,000,000 shares of Common Stock upon the exercise of stock options.  Options for the purchase of 1,889,931 shares under the 2008 Stock Option Plan were outstanding as of December 31, 2013.  Options for the purchase of 1,000,000 shares of Common Stock remain outstanding under an option granted to Mr. Thomas J. Shaw.
	The Compensation and Benefits Committee administers all plans and determines and/or recommends to the Board exercise prices at which options are granted.  All executive compensation, including the granting of stock options, is determined by the Compensation and Benefits Committee.  Shares issued upon exercise of options come from the Company’s authorized but unissued Common Stock.  The options vested over periods up to three years from the date of grant and generally expire ten years after the date of grant.  Unvested options issued under the 2008 Stock Option Plan expire immediately after termination of employment.
	Employee options
	A summary of Director, officer, and employee options granted and outstanding under the Plans is presented below:
			Years Ended December 31,
			2013					2012					2011
			Shares		Weighted			Shares		Weighted			Shares		Weighted
					Average					Average					Average
					Exercise					Exercise					Exercise
					Price					Price					Price
	Outstanding at beginning of period		3,367,081		$	0.95		5,433,591		$	0.91		5,508,513		$	0.91
	Granted		50,000		1.46			—		—			—		—
	Exercised		(584,450	)	(0.92		)	(2,000,865	)	(0.81		)	(67,122	)	(0.81		)
	Forfeited		(12,000	)	(2.38		)	(65,645	)	(2.29		)	(7,800	)	(0.85		)
	Outstanding at end of period		2,820,631		$	0.95		3,367,081		$	0.95		5,433,591		$	0.91
	Exercisable at end of period		2,820,631		$	0.95		3,367,081		$	0.95		5,433,591		$	0.91
	No employee options were issued in 2012 or 2011.  The fair value of the 2013 grant is $1.06 per share of underlying Common Stock and is estimated on the date of the grant using the Black Scholes pricing model with the following assumptions: expected volatility of 67.53%, risk free interest rate of 3.35%, and an expected life of 8.61 years.  This option was issued under the 2008 Stock Option Plan.
	The following table summarizes information about Director, officer, and employee options outstanding under the aforementioned plans at December 31, 2013:
	Exercise			Shares		Weighted		Shares
	Prices			Outstanding		Average		Exercisable
						Remaining
						Contractual
						Life
	$	8.87		700		0.36		700
	$	1.3		754,103		4.88		754,103
	$	1.46		50,000		9.37		50,000
	$	0.81		2,015,828		5.54		2,015,828
	Non-employee options
	A summary of options outstanding during the years ended December 31 and held by non-employees is as follows:
			Years Ended December 31,
			2013					2012					2011
			Shares		Weighted			Shares		Weighted			Shares		Weighted
					Average					Average					Average
					Exercise					Exercise					Exercise
					Price					Price					Price
	Outstanding at beginning of period		70,000		$	0.81		302,500		$	5.49		302,500		$	5.49
	Granted		—		—			—		—			—		—
	Exercised		—		—			—		—			—		—
	Forfeited		—		—			(232,500	)	(6.90		)	—		—
	Outstanding at end of period		70,000		$	0.81		70,000		$	0.81		302,500		$	5.49
	Exercisable at end of period		70,000		$	0.81		70,000		$	0.81		302,500		$	5.49
	No non-employee options were issued in 2011, 2012, or 2013.
	The following table summarizes information about non-employee options outstanding under the aforementioned plans at December 31, 2013:
	Exercise			Shares		Weighted Average		Shares
	Price			Outstanding		Remaining Contractual Life		Exercisable
	$	0.81		70,000		5.54		70,000
	The Company recorded $52,775; $0; and $0 as stock-based compensation expense in 2013, 2012, and 2011, respectively.  The total intrinsic value of options exercised was $1,210,135; $220,268; and $49,626 in 2013, 2012, and 2011, respectively.  The aggregate intrinsic value of options outstanding and exercisable with exercise prices lower than market price at December 31, 2013 was approximately $6,158,133.  There is no compensation cost related to non-vested stock options to be recognized in the future.
	Options Pricing Models – Assumptions
	The expected life and forfeiture rate assumptions are based on the vesting period for each option grant and expected exercise behavior.  The assumptions for expected volatility and dividend yield are based on recent historical experience.  Risk-free interest rates are set using grant-date U.S. Treasury yield curves for the same periods as the expected term.

401k_PLAN

401(k) PLAN	12 Months Ended
	Dec. 31, 2013
401(k) PLAN	'
401(k) PLAN	'
	18	401(k) PLAN
	The Company implemented an employee savings and retirement plan (the “401(k) Plan”) in 2005 that is intended to be a tax-qualified plan covering substantially all employees.  Under the terms of the 401(k) Plan, employees may elect to contribute up to 88% of their compensation, or the statutory prescribed limit, if less.  The Company may, at its discretion, match employee contributions.  In the third quarter of 2009, the Company discontinued its matching contributions until further notice.

BUSINESS_SEGMENTS

BUSINESS SEGMENTS	12 Months Ended
	Dec. 31, 2013
BUSINESS SEGMENTS	'
BUSINESS SEGMENTS	'
	19	BUSINESS SEGMENTS
			2013		2012		2011
	U.S. sales		$	24,843,200	$	25,363,814	$	26,655,781
	North and South America sales (excluding U.S.)		4,453,151		4,668,550		4,736,356
	Other international sales		1,488,776		3,612,139		710,159
	Total sales		$	30,785,127	$	33,644,503	$	32,102,296
	Long-lived assets
	U.S.		$	10,676,053	$	11,679,592	$	12,412,502
	International		$	234,119	$	220,058	$	241,354
	The Company does not operate in separate reportable segments.  The Company has minimal long-lived assets in foreign countries.  Shipments to international customers generally require a prepayment either by wire transfer or an irrevocable confirmed letter of credit.  The Company does extend credit to international customers on some occasions depending upon certain criteria, including, but not limited to, the credit worthiness of the customer, the stability of the country, banking restrictions, and the size of the order.  All transactions are in U.S. currency.

Schedule_IISchedule_of_Valuati

Schedule II-Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Schedule II - Schedule of Valuation and Qualifying Accounts	'
Schedule II - Schedule of Valuation and Qualifying Accounts	'
	Schedule II-Schedule of Valuation and Qualifying Accounts for the years ended December 31, 2013, 2012, and 2011:
			Balance at		Additions		Deductions		Balance at
			beginning						end of period
			of period
	Provision for Inventories
	Fiscal year ended 2011		$	205,600	$	52,835	$	—	$	258,435
	Fiscal year ended 2012		$	258,435	$	120,000	$	138,683	$	239,752
	Fiscal year ended 2013		$	239,752	$	530,000	$	88,357	$	681,395
	Provision for Accounts Receivables
	Fiscal year ended 2011		$	780,900	$	1,298,044	$	—	$	2,078,944
	Fiscal year ended 2012		$	2,078,944	$	107,246	$	—	$	2,186,190
	Fiscal year ended 2013		$	2,186,190	$	50,000	$	537,684	$	1,698,506
	Deferred Tax Valuation
	Fiscal year ended 2011		$	5,442,682	$	—	$	559,266	$	4,883,416
	Fiscal year ended 2012		$	4,883,416	$	1,155,638	$	—	$	6,039,054
	Fiscal year ended 2013		$	6,039,054	$	2,404,763	$	—	$	8,443,817
	Provision for Rebates				(A)		(B)		(C)
	Fiscal year ended 2011		$	11,102,329	$	19,229,308	$	14,172,842	$	16,158,795
	Fiscal year ended 2012		$	16,158,795	$	19,615,388	$	13,780,916	$	21,993,267
	Fiscal year ended 2013		$	21,993,267	$	17,912,447	$	13,112,048	$	26,793,666
	(A)	Represents estimated rebates deducted from gross revenues
	(B)	Represents rebates credited to the distributor and charge offs against the allowance
	(C)	Includes $3,611,962; $3,036,564; and $2,170,764 in Accounts payable for 2013, 2012 and 2011, respectively. The remainder includes a contra-account for credits taken by the distributor for which a credit memorandum has not been issued by the Company

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

'

Accounting estimates

'

Accounting estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.

Cash and cash equivalents

'

Cash and cash equivalents

For purposes of reporting cash flows, cash and cash equivalents include unrestricted cash, the proceeds subject to a stipulation (discussed elsewhere herein), money market accounts, and investments with original maturities of three months or less.

Accounts receivable

'

Accounts receivable

The Company records trade receivables when revenue is recognized.  No product has been consigned to customers.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  This provision is reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.

The Company requires certain customers to make a prepayment prior to beginning production or shipment of their order.  Customers may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in Other accrued liabilities on the Balance Sheets and are shown in Note 6, Other Accrued Liabilities.

The Company records an allowance for estimated returns as a reduction to Accounts receivable and Gross sales.  Historically, returns have been immaterial.

Inventories

'

Inventories

Inventories are valued at the lower of cost or market, with cost being determined using actual average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off.

Property, plant, and equipment

'

Property, plant, and equipment

Property, plant, and equipment are stated at cost.  Expenditures for maintenance and repairs are charged to operations as incurred.  Cost includes major expenditures for improvements and replacements which extend useful lives or increase capacity and interest cost associated with significant capital additions.  For the years ended December 31, 2013, 2012, and 2011, the Company capitalized interest of approximately $10,474; $36,596; and $57,000.  Gains or losses from property disposals are included in income.

Depreciation and amortization are calculated using the straight-line method over the following useful lives:

Production equipment

3 to 13 years

Office furniture and equipment

3 to 10 years

Buildings

39 years

Building improvements

15 years

Automobiles

7 years

Long-lived assets

'

Long-lived assets

The Company assesses the recoverability of long-lived assets using an assessment of the estimated undiscounted future cash flows related to such assets.  In the event that assets are found to be carried at amounts which are in excess of estimated gross future cash flows, the assets will be adjusted for impairment to a level commensurate with fair value determined using a discounted cash flow analysis of the underlying assets.

The Company’s property, plant, and equipment primarily consist of buildings, land, assembly equipment for syringes, molding machines, molds, office equipment, furniture, and fixtures.

Intangible assets

'

Intangible assets

Intangible assets are stated at cost and consist primarily of intellectual property which is amortized using the straight-line method over 17 years.

Financial instruments

'

Financial instruments

The Company estimates the fair market value of financial instruments through the use of public market prices, quotes from financial institutions, and other available information.  Judgment is required in interpreting data to develop estimates of market value and, accordingly, amounts are not necessarily indicative of the amounts that could be realized in a current market exchange.  Short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on Management’s estimates, equals their recorded values.  The fair value of long-term liabilities, based on Management’s estimates, approximates their reported values.

Concentration risks

'

Concentration risks

The Company’s financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable.  Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality.  The majority of accounts receivable are due from companies which are well-established entities.  As a consequence, Management considers any exposure from concentrations of credit risks to be limited.

The following table reflects our significant customers in 2013, 2012, and 2011:

Years Ended December 31,

2013

2012

2011

Number of significant customers

2

3

4

Aggregate dollar amount of net sales to significant customers

$9.3 million

$13.7 million

$16.2 million

Percentage of net sales to significant customers

30.20%

40.60%

50.60%

Considering the current economic climate, the Company increased its allowance for doubtful accounts by approximately $50,000 this year.

The Company manufactures syringes in Little Elm, Texas as well as utilizing manufacturers in China.  The Company purchases most of its product components from single suppliers, including needle adhesives and packaging materials.  There are multiple sources of these materials.  The Company obtained roughly 72.9% of its finished products in 2013 from Double Dove, a Chinese manufacturer.  Purchases from Double Dove aggregated 72.0% and 67.1% of finished products in 2012 and 2011, respectively.  In the event that the Company becomes unable to purchase such product from Double Dove, the Company would need to find an alternate manufacturer for its 0.5mL insulin syringe, its 2mL, 5mL, and 10mL syringes and its autodisable syringe and increase domestic production for 1mL and 3mL syringes.

Revenue recognition

'

Revenue recognition

Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment.  Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances.  Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products that the Company has not received tracking reports.  Rebates are recorded when issued and are applied against the customer’s receivable balance.  Distributors receive a rebate for the difference between the Wholesale Acquisition Cost and the appropriate contract price as reflected on a tracking report provided by the distributor to the Company. If product is sold by a distributor to an entity that has no contract, there is a standard rebate (lower than a contracted rebate) given to the distributor.  One of the purposes of the rebate is to encourage distributors to submit tracking reports to the Company. The provision for contractual pricing allowances is reviewed at the end of each quarter and adjusted for changes in levels of products for which there is no tracking report.  Additionally, if it becomes clear that tracking reports will not be provided by individual distributors, the provision is further adjusted.  The estimated contractual allowance is included in Accounts payable and deducted from revenues in the Statements of Operations.  Accounts payable included estimated contractual allowances for $3,611,692 and $3,036,564 for 2013 and 2012, respectively.  The terms and conditions of contractual pricing allowances are governed by contracts between the Company and its distributors.  Revenue for shipments directly to end-users is recognized when title and risk of ownership pass from the Company.  Any product shipped or distributed for evaluation purposes is expensed.

Certain distributors have taken rebates to which they are not entitled, such as utilizing a rebate for products not purchased directly from the Company.  Major customers said they have ceased the practices resulting in claiming non-contractual rebates.  Rebates can only be claimed on purchases made directly from the Company. The Company has established a reserve for the collectability of these non-contractual rebate amounts.  The expense for the reserve is recorded in Operating expense, General and administrative.  The reserve for such non-contractual deductions is included in the allowance for doubtful accounts.  There has been no change to the reserve contractual rebates in the periods currently presented.

The Company’s domestic return policy is set forth in its standard Distribution Agreement.  This policy provides that a customer may return incorrect shipments within 10 days following arrival at the distributor’s facility.  In all such cases the distributor must obtain an authorization code from the Company and affix the code to the returned product.  The Company will not accept returned goods without a returned goods authorization number.  The Company may refund the customer’s money or replace the product.

The Company’s domestic return policy also provides that a customer may return product that is overstocked.  Overstocking returns are limited to two times in each 12-month period up to 1% of distributor’s total purchase of products for the prior 12-month period.  All product overstocks and returns are subject to inspection and acceptance by the Company.

The Company’s international distribution agreements do not provide for any returns.

Litigation proceeds and settlements

'

Litigation proceeds and settlements

Proceeds from litigation are recognized when realizable.  Generally, realization is not reasonably assured and expected until proceeds are collected; however, see Note 8, COMMITMENTS AND CONTINGENCIES, for a discussion of proceeds received from Becton Dickinson and Company (“BD”) pursuant to a stipulation in the patent infringement case Retractable Technologies, Inc. and Thomas Shaw v. Becton Dickinson and Company, Civil Action No. 2:07-cv-250, in the U.S. District Court for the Eastern District of Texas, Marshall Division.

Pursuant to a settlement agreement among the Company, Abbott, and Hospira, Inc. (“Hospira”), Hospira delivered $6 million to the Company in the third quarter of 2010.  The Company reduced its litigation settlements by $144,000 attributable to an unpaid Abbott invoice.  Abbott also waived its rights to any Series IV Class B Preferred Stock dividends.  Additionally, the Company granted Hospira an exclusive one-year option to negotiate a licensing agreement for certain uses of the Patient Safe® syringe, which option expired unexercised in July 2011.  The Company has received the $8.0 million option payments.  The Company recognizes proceeds from litigation settlements, net of any associated royalty expense.

Income taxes

'

Income taxes

The Company evaluates tax positions taken or expected to be taken in a tax return for recognition in the financial statements based on whether it is “more-likely-than-not” that a tax position will be sustained based upon the technical merits of the position.  Measurement of the tax position is based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.

The Company provides for deferred income taxes through utilizing an asset and liability approach for financial accounting and reporting based on the tax effects of differences between the financial statement and tax bases of assets and liabilities, based on enacted rates expected to be in effect when such differences reverse in future periods.  Deferred tax assets are periodically reviewed for realizability.  The Company utilized some of its net operating loss carry forwards in 2011 and 2013 and paid Alternative Minimum Tax on its taxable income.  The Company has established a valuation allowance for its net deferred tax asset as future taxable income cannot be reasonably assured.  Penalties and interest related to income tax are classified as General and administrative expense and Interest expense, respectively, in the Statements of Operations.

Earnings per share

'

Earnings per share

The Company computes basic earnings per share (“EPS”) by dividing net earnings for the period (adjusted for any cumulative dividends for the period) by the weighted average number of common shares outstanding during the period.  Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect, if any, of the common stock deliverable pursuant to stock options or common stock issuable upon the conversion of convertible preferred stock and convertible debt.  The calculation of diluted EPS excluded 1,305,847 and 1,373,345 shares of Common Stock underlying issued and outstanding stock options at December 31, 2013 and 2012, respectively, as their effect was antidilutive.  The potential dilution, if any, is shown on the following schedule:

Years Ended December 31,

2013

2012

2011

Net income (loss)

$

(6,213,852

)

$

(4,132,892

)

$

1,418,482

Preferred dividend requirements

(916,065

)

(918,108

)

(964,047

)

Effect of dilutive securities:

Convertible debt interest and loan fees

—

—

(10,120

)

Earnings (loss) applicable to common shareholders after assumed conversions

$

(7,129,917

)

$

(5,051,000

)

$

444,315

Average common shares outstanding

26,999,698

26,219,728

24,171,238

Dilutive stock equivalents from stock options

—

—

2,101,825

Shares issuable upon conversion of convertible debt

—

—

81,723

Average common and common equivalent shares outstanding - assuming dilution

26,999,698

26,219,728

26,354,786

Basic earnings (loss) per share

$

(0.26

)

$

(0.19

)

$

0.02

Diluted earnings (loss) per share

$

(0.26

)

$

(0.19

)

$

0.02

Shipping and handling costs

'

Shipping and handling costs

The Company classifies shipping and handling costs as part of Cost of sales in the Statements of Operations.

Research and development costs

'

Research and development costs

Research and development costs are expensed as incurred.

Share-based compensation

'

Share-based compensation

The Company’s share-based payments are accounted for using the fair value method.  The Company records share-based compensation expense on a straight-line basis over the requisite service period.  The Company incurred $52,775 in General and administrative cost related to share-based compensation in 2013.  No other departments or years incurred share-based compensation costs.

All stock options are fully vested; therefore, all stock option expense has been fully recognized.

Recent Pronouncement

'

Recent Pronouncement

In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”).  ASU 2013-11 requires, unless certain conditions exists, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward.  ASU 2013-11 is effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted.  Retrospective application is also permitted.  The adoption of ASU 2013-11, effective with the reporting period beginning January 1, 2014, is not expected to have an impact on the Company’s financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Schedule of estimated useful lives of property, plant and equipment	'
	Production equipment		3 to 13 years
	Office furniture and equipment		3 to 10 years
	Buildings		39 years
	Building improvements		15 years
	Automobiles		7 years
Schedule of significant customers	'
			Years Ended December 31,
			2013		2012		2011
	Number of significant customers		2		3		4
	Aggregate dollar amount of net sales to significant customers		$9.3 million		$13.7 million		$16.2 million
	Percentage of net sales to significant customers		30.20%		40.60%		50.60%
Schedule of earnings per share	'
			Years Ended December 31,
			2013				2012				2011
	Net income (loss)	$		(6,213,852	)	$		(4,132,892	)	$		1,418,482
	Preferred dividend requirements		(916,065		)		(918,108		)		(964,047		)
	Effect of dilutive securities:
	Convertible debt interest and loan fees		—				—				(10,120		)
	Earnings (loss) applicable to common shareholders after assumed conversions	$		(7,129,917	)	$		(5,051,000	)	$		444,315
	Average common shares outstanding		26,999,698				26,219,728				24,171,238
	Dilutive stock equivalents from stock options		—				—				2,101,825
	Shares issuable upon conversion of convertible debt		—				—				81,723
	Average common and common equivalent shares outstanding - assuming dilution		26,999,698				26,219,728				26,354,786
	Basic earnings (loss) per share	$		(0.26	)	$		(0.19	)	$		0.02
	Diluted earnings (loss) per share	$		(0.26	)	$		(0.19	)	$		0.02

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
INVENTORIES	'
Schedule of inventories	'
		Year Ended December 31,
		2013			2012
	Raw materials	$	1,666,525		$	1,692,133
	Finished goods	4,750,459			3,537,872
		2013			2012
		6,416,984			5,230,005
	Inventory reserve	(681,395		)	(239,752		)
		$	5,735,589		$	4,990,253

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT, AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY, PLANT, AND EQUIPMENT	'
Schedule of property, plant, and equipment	'
		December 31,
		2013			2012
	Land	$	261,893		$	261,893
	Buildings and building improvements	11,389,181			11,354,210
	Production equipment	15,602,709			15,612,807
	Office furniture and equipment	3,114,451			2,821,179
	Construction in progress	610,679			731,258
	Automobiles	102,321			102,321
		31,081,234			30,883,668
	Accumulated depreciation	(20,171,062		)	(18,984,018		)
		$	10,910,172		$	11,899,650

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS	'
Schedule of intangible assets	'
		December 31,
		2013			2012
	Intellectual property	$	494,399		$	494,399
	Accumulated amortization	(219,358		)	(207,879		)
		$	275,041		$	286,520

OTHER_ACCRUED_LIABILITIES_Tabl

OTHER ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
OTHER ACCRUED LIABILITIES	'
Schedule of other accrued liabilities	'
			December 31,
			2013			2012
	Prepayments from customers	$		1,720,896	$		1,400,740
	Accrued professional fees		169,125			162,969
	Other accrued expenses		84,997			101,961
		$		1,975,018	$		1,665,670

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2013
LONG-TERM DEBT	'
Schedule of long-term debt	'
		December 31,
		2013			2012
	Long-term debt consists of the following:
	Loan from American First National Bank. It has a 20 year amortization and 10 year maturity from December 10, 2009. The loan provided funding for the expansion of the warehouse, additional office space, and a new Controlled Environment. The loan is secured by the Company’s land and buildings. The interest rate is 5.968%.	$	3,717,795		$	3,852,512
	Note payable to Deutsche Leasing USA, Inc. The interest rate is 5.57%. The original amount of the note was $327,726 with a 36 month maturity ending in April 2014. In May 2011, the loan became payable in equal installments of principal and interest of approximately $9,900. Collateralized by three molding machines. It has a purchase option of $1.00 at the end of the term.	39,169			152,415
	Note payable to Deutsche Leasing USA, Inc. The interest rate is 5.57%. The original amount of the note was $207,260 with a 36 month maturity ending in November 2014. Beginning December 2011, the loan became payable in equal installments of principal and interest of approximately $6,300. Collateralized by a molding machine. It has a purchase option of $1.00 at the end of the term.	67,032			136,369
		3,823,996			4,141,296
	Less: current portion	(247,064		)	(315,086		)
		$	3,576,932		$	3,826,210
Schedule of aggregate maturities of long-term debt	'
	The aggregate maturities of long-term debt as of December 31, 2013, are as follows:
	2014	$	247,064
	2015	149,742
	2016	159,182
	2017	169,211
	2018	179,868
	Thereafter	2,918,929
		$	3,823,996

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES	'
Schedule of future annual minimum rental payments under non-cancellable operating lease	'
	Future annual minimum rental payments as of December 31, 2013 are presented below:
	2014	$	62,813
	2015		59,966
	Total	$	122,779

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
Schedule of provision for income taxes	'
			For the Years Ended December 31,
			2013			2012			2011
	Current tax provision (benefit)
	Federal		$	83,470		$	1,785		$	(29,070	)
	State		7,502			8,033			42,867
	Total current provision (benefit)		90,972			9,818			13,797
	Deferred tax provision (benefit)
	Federal		—			—			—
	State		—			—			—
	Total deferred tax provision (benefit)		—			—			—
	Total income tax provision (benefit)		$	90,972		$	9,818		$	13,797
Schedule of tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities	'
			December 31,
			2013			2012
	Deferred tax assets
	Net operating loss carry forwards	$	3,819,961	$		4,873,433
	Credit for alternative minimum tax paid		83,470			—
	Accrued expenses and reserves		1,350,125			1,165,658
	Employee stock option expense		315,711			295,696
	Inventory		338,253			319,830
	Non-employee stock option expense		—			15,546
	Litigation proceeds subject to stipulation		2,929,640			—
	Deferred tax assets		8,837,160			6,670,163
	Deferred tax liabilities
	Property and equipment		(393,343	)		(631,109	)
	Deferred tax liabilities		(393,343	)		(631,109	)
	Net deferred assets		8,443,817			6,039,054
	Valuation allowance		(8,443,817	)		(6,039,054	)
	Net deferred tax assets	$	—	$		—
Schedule of reconciliation of income taxes based on the federal statutory rate and the provision (benefit) for income taxes	'
			December 31,
			2013		2012		2011
	Income tax (benefit) at the federal statutory rate		35	%	35	%	35	%
	State tax (benefit), net of federal (benefit)		2.9		2.9		2.9
	Decrease (increase) in valuation allowance		(39.3	)	(28.0	)	—
	Permanent differences		(0.3	)	1.2		2
	Return to accrual adjustments		—		—		(2.8	)
	Alternative minimum tax		(1.4	)	—		3.4
	Adjustments to temporary differences for stock options		—		(11.0	)	—
	Release of valuation allowance – Net operating loss carry forward		—		—		(39.0	)
	Other		1.6		(0.3	)	(0.5	)
	Effective tax (benefit) rate		(1.5	)%	(0.2	)%	1	%

EXCHANGE_OF_PREFERRED_STOCK_FO1

EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH (Tables)	12 Months Ended
	Dec. 31, 2013
EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH	'
Summary of 2011 Exchange Offer and private sales	'
		Number of	Cash Outlay		Number of	Accrued		Amount of
		Preferred	by Company		Common	Dividends		Annual
		Stock Shares			Stock Shares	Eliminated		Dividend
		Tendered by			Tendered by			Reduction
		Preferred			Company
		Stockholders
	Series I Class B Stock	40,500	$	60,750	40,500	$	—	$	20,250
	Series II Class B Stock	41,000	123,000		41,000	—		41,000
	Series IV Class B Stock	10,000	35,000		10,000	114,575		10,000
	Series V Class B Stock	1,185,964	1,138,525		1,185,964	3,478,084		379,508
	Total Class B Stock	1,277,464	$	1,357,275	1,277,464	$	3,592,659	$	450,758

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Employee options	'
Stock option grant	'
Summary of options outstanding	'
			Years Ended December 31,
			2013					2012					2011
			Shares		Weighted			Shares		Weighted			Shares		Weighted
					Average					Average					Average
					Exercise					Exercise					Exercise
					Price					Price					Price
	Outstanding at beginning of period		3,367,081		$	0.95		5,433,591		$	0.91		5,508,513		$	0.91
	Granted		50,000		1.46			—		—			—		—
	Exercised		(584,450	)	(0.92		)	(2,000,865	)	(0.81		)	(67,122	)	(0.81		)
	Forfeited		(12,000	)	(2.38		)	(65,645	)	(2.29		)	(7,800	)	(0.85		)
	Outstanding at end of period		2,820,631		$	0.95		3,367,081		$	0.95		5,433,591		$	0.91
	Exercisable at end of period		2,820,631		$	0.95		3,367,081		$	0.95		5,433,591		$	0.91
Schedule of information about stock options by range of exercise prices	'
	The following table summarizes information about Director, officer, and employee options outstanding under the aforementioned plans at December 31, 2013:
	Exercise			Shares		Weighted		Shares
	Prices			Outstanding		Average		Exercisable
						Remaining
						Contractual
						Life
	$	8.87		700		0.36		700
	$	1.3		754,103		4.88		754,103
	$	1.46		50,000		9.37		50,000
	$	0.81		2,015,828		5.54		2,015,828
Non-employee options	'
Stock option grant	'
Summary of options outstanding	'
			Years Ended December 31,
			2013					2012					2011
			Shares		Weighted			Shares		Weighted			Shares		Weighted
					Average					Average					Average
					Exercise					Exercise					Exercise
					Price					Price					Price
	Outstanding at beginning of period		70,000		$	0.81		302,500		$	5.49		302,500		$	5.49
	Granted		—		—			—		—			—		—
	Exercised		—		—			—		—			—		—
	Forfeited		—		—			(232,500	)	(6.90		)	—		—
	Outstanding at end of period		70,000		$	0.81		70,000		$	0.81		302,500		$	5.49
	Exercisable at end of period		70,000		$	0.81		70,000		$	0.81		302,500		$	5.49
Schedule of information about stock options by range of exercise prices	'
	The following table summarizes information about non-employee options outstanding under the aforementioned plans at December 31, 2013:
	Exercise			Shares		Weighted Average		Shares
	Price			Outstanding		Remaining Contractual Life		Exercisable
	$	0.81		70,000		5.54		70,000

BUSINESS_SEGMENTS_Tables

BUSINESS SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
BUSINESS SEGMENTS	'
Schedule of sales and long-lived assets by geographical areas	'
		2013		2012		2011
	U.S. sales	$	24,843,200	$	25,363,814	$	26,655,781
	North and South America sales (excluding U.S.)	4,453,151		4,668,550		4,736,356
	Other international sales	1,488,776		3,612,139		710,159
	Total sales	$	30,785,127	$	33,644,503	$	32,102,296
	Long-lived assets
	U.S.	$	10,676,053	$	11,679,592	$	12,412,502
	International	$	234,119	$	220,058	$	241,354

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item
Accounts receivable	'	'	'
Number of products consigned to customers	0	'	'
Property, plant, and equipment	'	'	'
Capitalized interest	$10,474	$36,596	$57,000
Intangible assets	'	'	'
Useful lives of intellectual property	'17 years	'	'
Production equipment | Minimum	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'3 years	'	'
Production equipment | Maximum	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'13 years	'	'
Office furniture and equipment | Minimum	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'3 years	'	'
Office furniture and equipment | Maximum	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'10 years	'	'
Buildings	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'39 years	'	'
Building improvements	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'15 years	'	'
Automobiles	'	'	'
Property, plant, and equipment	'	'	'
Useful lives	'7 years	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item	item	item
Concentration risks	'	'	'
Number of significant customers	2	3	4
Aggregate dollar amount of net sales to significant customers	$30,785,127	$33,644,503	$32,102,296
Increase in allowance for doubtful accounts	50,000	107,246	1,298,044
Revenue recognition	'	'	'
Estimated contractual allowance	3,611,692	3,036,564	'
Change to reserve regarding non-contractual rebates	0	'	'
Period for return of incorrect shipments	'10 days	'	'
Number of times overstocking returns are limited	2	'	'
Period for return of product due to overstock	'12 months	'	'
Maximum percentage of distributor's total purchase for the prior 12-month period	1.00%	'	'
Customer concentration risk	'	'	'
Concentration risks	'	'	'
Increase in allowance for doubtful accounts	50,000	'	'
Sales | Customer concentration risk	'	'	'
Concentration risks	'	'	'
Aggregate dollar amount of net sales to significant customers	$9,300,000	$13,700,000	$16,200,000
Concentration risk (as a percent)	30.20%	40.60%	50.60%
Product components | Supplier concentration risk	'	'	'
Concentration risks	'	'	'
Concentration risk (as a percent)	72.90%	72.00%	67.10%

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) (Litigation settlements, USD $)	3 Months Ended	11 Months Ended	12 Months Ended
	Sep. 30, 2010	Jul. 31, 2011	Dec. 31, 2013
Hospira	'	'	'
Litigation settlements	'	'	'
Litigation settlements received	$6,000,000	'	'
Period for option to negotiate licensing agreement	'	'1 year	'
Option payment received	'	'	8,000,000
Abbott	'	'	'
Litigation settlements	'	'	'
Reduction in litigation settlement amount attributable to an unpaid Abbott invoice	'	'	$144,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings per share	'	'	'
Shares of common stock underlying issued and outstanding stock options excluded from calculation of diluted EPS	1,305,847	1,373,345	'
Net income (loss)	($6,213,852)	($4,132,892)	$1,418,482
Preferred dividend requirements	-916,065	-918,108	-964,047
Effect of dilutive securities: Convertible debt interest and loan fees	'	'	-10,120
Earnings (loss) applicable to common shareholders	($7,129,917)	($5,051,000)	$454,435
Average common shares outstanding	26,999,698	26,219,728	24,171,238
Dilutive stock equivalents from stock options (in shares)	'	'	2,101,825
Shares issuable upon conversion of convertible debt	'	'	81,723
Average common and common equivalent shares outstanding - assuming dilution	26,999,698	26,219,728	26,354,786
Basic earnings (loss) per share (in dollars per share)	($0.26)	($0.19)	$0.02
Diluted earnings (loss) per share (in dollars per share)	($0.26)	($0.19)	$0.02

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based compensation costs:	'	'	'
Share-based compensation expense	$52,775	$0	$0
General and administrative	'	'	'
Share-based compensation costs:	'	'	'
Share-based compensation expense	$52,775	'	'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
INVENTORIES	'	'
Raw materials	$1,666,525	$1,692,133
Finished goods	4,750,459	3,537,872
Inventory, gross	6,416,984	5,230,005
Inventory reserve	-681,395	-239,752
Inventory, net	$5,735,589	$4,990,253

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT, AND EQUIPMENT (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	$31,081,234	$30,883,668	'
Accumulated depreciation	-20,171,062	-18,984,018	'
Property, plant and equipment, net	10,910,172	11,899,650	'
Depreciation expense	1,272,770	1,264,326	1,267,813
Land	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	261,893	261,893	'
Buildings and building improvements	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	11,389,181	11,354,210	'
Production equipment	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	15,602,709	15,612,807	'
Office furniture and equipment	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	3,114,451	2,821,179	'
Construction in progress	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	610,679	731,258	'
Automobiles	'	'	'
Property, plant, and equipment	'	'	'
Property, plant and equipment, gross	$102,321	$102,321	'

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible assets	'	'	'
Accumulated amortization	($219,358)	($207,879)	'
Intangible assets net	275,041	286,520	'
Amortization period of license fee	'17 years	'	'
Royalty fees	2,474,762	2,691,887	2,643,209
Amortization expense	11,479	71,532	43,934
Future amortization expense	'	'	'
2014	11,479	'	'
2015	11,479	'	'
2016	11,479	'	'
2017	11,479	'	'
2018	11,479	'	'
License agreement	'	'	'
Intangible assets	'	'	'
Initial licensing fee	500,000	'	'
Amortization period of license fee	'17 years	'	'
Quarterly payments as a percentage of royalty fee on gross sales	5.00%	'	'
Royalty fees	2,474,762	2,691,887	2,643,209
Royalty payable under the license agreement	602,209	129,107	'
Gross sales upon which royalties are based	49,495,232	53,837,732	52,864,158
Intellectual property	'	'	'
Intangible assets	'	'	'
Intangible assets gross	$494,399	$494,399	'

OTHER_ACCRUED_LIABILITIES_Deta

OTHER ACCRUED LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
OTHER ACCRUED LIABILITIES	'	'
Prepayments from customers	$1,720,896	$1,400,740
Accrued professional fees	169,125	162,969
Other accrued expenses	84,997	101,961
Other accrued liabilities	$1,975,018	$1,665,670

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Long-term debt	'	'
Long term debt total	$3,823,996	$4,141,296
Less: current portion	-247,064	-315,086
Long term debt, excluding current maturities	3,576,932	3,826,210
Loan from American First National Bank	'	'
Long-term debt	'	'
Long term debt total	3,717,795	3,852,512
Amortization period	'20 years	'20 years
Maturity period of debt instrument	'10 years	'10 years
Interest rate (as a percent)	5.97%	5.97%
Note payable to Deutsche Leasing USA, Inc. due April 2014, 5.57%	'	'
Long-term debt	'	'
Long term debt total	39,169	152,415
Maturity period of debt instrument	'36 months	'36 months
Interest rate (as a percent)	5.57%	5.57%
Original amount of note	327,726	327,726
Installments of principal and interest	9,900	9,900
Number of molding machines used to collateralized debt	3	3
Purchase option price (in dollars per share)	$1	$1
Note payable to Deutsche Leasing USA, Inc. due November 2014, 5.57%	'	'
Long-term debt	'	'
Long term debt total	67,032	136,369
Maturity period of debt instrument	'36 months	'36 months
Interest rate (as a percent)	5.57%	5.57%
Original amount of note	207,260	207,260
Installments of principal and interest	$6,300	$6,300
Purchase option price (in dollars per share)	$1	$1

LONGTERM_DEBT_Details_2

LONG-TERM DEBT (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Aggregate maturities of long-term debt	'	'
2014	$247,064	'
2015	149,742	'
2016	159,182	'
2017	169,211	'
2018	179,868	'
Thereafter	2,918,929	'
Total	$3,823,996	$4,141,296

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended			0 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Sep. 19, 2013	Jul. 31, 2011	31-May-10	Sep. 30, 2007
				BD	BD	BD	BD	BD and MDC Investment Holdings, Inc.
						item		item
COMMITMENTS AND CONTINGENCIES	'	'	'	'	'	'	'	'
Recovery amount	'	'	'	'	'	'	$5,000,000	'
Period from specified date for permanent injunction to stay	'	'	'	'	'	'	'12 months	'
Number of judges on panel	'	'	'	'	'	3	'	'
Number of dissents being issued	'	'	'	'	'	2	'	'
Judgment amount received pursuant to stipulation	'	'	'	7,724,826	'	'	'	'
Value of damages awarded	'	'	'	'	113,508,014	'	'	'
Number of U.S. patents infringed upon	'	'	'	'	'	'	'	2
Operating Leases	'	'	'	'	'	'	'	'
Rent expense under operating lease	61,607	60,401	59,195	'	'	'	'	'
Future annual minimum rental payments	'	'	'	'	'	'	'	'
2014	62,813	'	'	'	'	'	'	'
2015	59,966	'	'	'	'	'	'	'
Total	$122,779	'	'	'	'	'	'	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current tax provision (benefit)	'	'	'
Federal	$83,470	$1,785	($29,070)
State	7,502	8,033	42,867
Total current provision (benefit)	90,972	9,818	13,797
Total income tax provision (benefit)	90,972	9,818	13,797
Tax benefits attributable to carryback losses for federal tax purposes	10,072,410	'	'
Deferred tax assets	'	'	'
Net operating loss carryforwards	3,819,961	4,873,433	'
Credit for alternative minimum tax paid	83,470	'	'
Accrued expenses and reserves	1,350,125	1,165,658	'
Employee stock option expense	315,711	295,696	'
Inventory	338,253	319,830	'
Non-employee stock option expense	'	15,546	'
Litigation proceeds subject to stipulation	2,929,640	'	'
Deferred tax assets	8,837,160	6,670,163	'
Deferred tax liabilities	'	'	'
Property and equipment	-393,343	-631,109	'
Deferred tax liabilities	-393,343	-631,109	'
Net deferred assets	8,443,817	6,039,054	'
Valuation allowance	-8,443,817	-6,039,054	'
Increase in valuation allowance	$2,404,763	$1,155,638	'
Reconciliation of income taxes based on the federal statutory rate and the provision (benefit) for income taxes	'	'	'
Income tax (benefit) at the federal statutory rate (as a percent)	35.00%	35.00%	35.00%
State tax (benefit), net of federal (benefit) (as a percent)	2.90%	2.90%	2.90%
Decrease (increase) in valuation allowance (as a percent)	-39.30%	-28.00%	'
Permanent differences (as a percent)	-0.30%	1.20%	2.00%
Return to accrual adjustments (as a percent)	'	'	-2.80%
Alternative minimum tax (as a percent)	-1.40%	'	3.40%
Adjustment to temporary difference for stock options	'	-11.00%	'
Release of valuation allowance - Net operating loss carryforward (as a percent)	'	'	-39.00%
Other (as a percent)	1.60%	-0.30%	-0.50%
Effective tax (benefit) rate (as a percent)	-1.50%	-0.20%	1.00%
Minimum	'	'	'
Income tax examination	'	'	'
State and local income tax returns, period subject to examination	'3 years	'	'
Maximum	'	'	'
Income tax examination	'	'	'
State and local income tax returns, period subject to examination	'5 years	'	'

EXCHANGE_OF_PREFERRED_STOCK_FO2

EXCHANGE OF PREFERRED STOCK FOR COMMON STOCK AND CASH (Details) (USD $)	12 Months Ended	0 Months Ended	12 Months Ended
	Dec. 31, 2011	Sep. 12, 2011	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2011
		Private sales	Series I Class B Stock	Series II Class B Stock	Series IV Class B Stock	Series V Class B Stock
		item
Exchange Offer and private sales	'	'	'	'	'	'
Number of preferred stockholders	'	3	'	'	'	'
Number of Preferred Stock Shares Tendered by Preferred Stockholders	1,277,464	'	40,500	41,000	10,000	1,185,964
Cash Outlay by Company	$1,357,275	'	$60,750	$123,000	$35,000	$1,138,525
Number of Common Stock Shares Tendered by Company	1,277,464	'	40,500	41,000	10,000	1,185,964
Accrued Dividends Eliminated	3,592,659	'	'	'	114,575	3,478,084
Amount of Annual Dividend Reduction	$450,758	'	$20,250	$41,000	$10,000	$379,508

STOCK_REPURCHASE_PROGRAM_Detai

STOCK REPURCHASE PROGRAM (Details) (USD $)	0 Months Ended								12 Months Ended
	Jan. 20, 2014	Dec. 20, 2013	Nov. 11, 2013	Jul. 22, 2013	Apr. 22, 2013	Jan. 21, 2013	Oct. 22, 2012	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock repurchase program	'	'	'	'	'	'	'	'	'	'	'
Stock repurchased under the Common Stock repurchase plan (in shares)	'	'	'	'	'	'	'	'	655,818	67,102	'
Preferred stock dividends paid	'	'	'	'	'	'	'	'	$230,449	$230,450	$364,625
Series I, Class B	'	'	'	'	'	'	'	'	'	'	'
Stock repurchase program	'	'	'	'	'	'	'	'	'	'	'
Preferred stock dividends paid	12,938	12,938	12,938	12,938	12,938	12,938	12,938	38,813	38,814	51,751	90,000
Series II, Class B	'	'	'	'	'	'	'	'	'	'	'
Stock repurchase program	'	'	'	'	'	'	'	'	'	'	'
Preferred stock dividends paid	$44,675	'	$44,675	$44,675	$44,675	$44,675	$44,675	$134,025	$134,025	$178,700	$274,625

STOCK_OPTION_GRANT_Details

STOCK OPTION GRANT (Details) (USD $)	12 Months Ended				0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	14-May-13
				Non-qualified stock option	Non-qualified stock option
				2008 Stock Option Plan	2008 Stock Option Plan
					Walter O. Bigby, Jr.
Stock option grant	'	'	'	'	'
Shares of Common Stock granted	'	'	'	1,889,931	50,000
Share-based compensation expense	$52,775	$0	$0	'	$52,775

DIVIDENDS_Details

DIVIDENDS (Details) (USD $)	0 Months Ended								12 Months Ended
	Jan. 20, 2014	Dec. 20, 2013	Nov. 11, 2013	Jul. 22, 2013	Apr. 22, 2013	Jan. 21, 2013	Oct. 22, 2012	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Dividends	'	'	'	'	'	'	'	'	'	'	'
Preferred stock dividends paid	'	'	'	'	'	'	'	'	$230,449	$230,450	$364,625
Series I, Class B	'	'	'	'	'	'	'	'	'	'	'
Dividends	'	'	'	'	'	'	'	'	'	'	'
Preferred stock dividends paid	12,938	12,938	12,938	12,938	12,938	12,938	12,938	38,813	38,814	51,751	90,000
Series II, Class B	'	'	'	'	'	'	'	'	'	'	'
Dividends	'	'	'	'	'	'	'	'	'	'	'
Preferred stock dividends paid	$44,675	'	$44,675	$44,675	$44,675	$44,675	$44,675	$134,025	$134,025	$178,700	$274,625

STOCK_OPTION_EXERCISES_Details

STOCK OPTION EXERCISES (Details) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 10, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2009	Dec. 31, 2008
				Stock Option	Stock Option	Stock Option	Stock Option	Stock Option	Stock Option
				Chief Executive Officer	Employee	Employee	Employee	Employee	Employee
STOCK OPTION EXERCISES	'	'	'	'	'	'	'	'	'
Number of shares of common stock issued	'	'	'	2,000,000	584,450	2,000,865	67,122	'	'
Exercise price (in dollars per share)	'	'	'	$0.81	$0.92	$0.81	$0.81	'	'
Exercise price (in dollars per share)	'	'	'	'	$1.46	'	'	$1.30	$0.81
Aggregate consideration from issue of common stock	$536,925	$1,620,701	$54,369	$1,620,000	$536,925	'	'	'	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	0 Months Ended								12 Months Ended
	Jan. 20, 2014	Dec. 20, 2013	Nov. 11, 2013	Jul. 22, 2013	Apr. 22, 2013	Jan. 21, 2013	Oct. 22, 2012	Jul. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Number of classes of preferred stock outstanding	'	'	'	'	'	'	'	'	1	'	'
Dividend paid	'	'	'	'	'	'	'	'	$230,449	$230,450	$364,625
Common stock authorized (in shares)	'	'	'	'	'	'	'	'	100,000,000	100,000,000	'
Common stock outstanding (in shares)	'	'	'	'	'	'	'	'	27,187,702	27,252,463	'
Preferred Stock Class A	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock authorized (in shares)	'	'	'	'	'	'	'	'	5,000,000	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	'	'
Preferred Stock Class B	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock authorized (in shares)	'	'	'	'	'	'	'	'	5,000,000	5,000,000	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Number of series of preferred stock class B	'	'	'	'	'	'	'	'	5	'	'
Preferred stock, remaining authorized shares to which series have Not been assigned	'	'	'	'	'	'	'	'	4,005,055	'	'
Series I Class B	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Preferred stock outstanding (in shares)	'	'	'	'	'	'	'	'	103,500	103,500	'
Cumulative annual dividend payable quarterly (in dollars per share)	'	'	'	'	'	'	'	'	$0.50	'	'
Dividend paid	12,938	12,938	12,938	12,938	12,938	12,938	12,938	38,813	38,814	51,751	90,000
Preferred stock dividend in arrears	'	'	'	'	'	'	'	'	13,000	'	'
Period after which stock is redeemable at the option of the entity	'	'	'	'	'	'	'	'	'3 years	'	'
Preferred stock redemption price (in dollars per share)	'	'	'	'	'	'	'	'	$7.50	'	'
Preferred stock conversion ratio	'	'	'	'	'	'	'	'	1	'	'
Period after which stock can be converted at the option of the stockholders	'	'	'	'	'	'	'	'	'3 years	'	'
Number of shares of preferred stock converted into common stock	'	'	'	'	'	'	'	'	0	0	'
Amount per share the holders of the preferred stock entitled to in voluntary or involuntary dissolution, liquidation or winding up of the Company (in dollars per share)	'	'	'	'	'	'	'	'	$6.25	'	'
Series II Class B	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Preferred stock outstanding (in shares)	'	'	'	'	'	'	'	'	178,700	178,700	'
Cumulative annual dividend payable quarterly (in dollars per share)	'	'	'	'	'	'	'	'	$1	'	'
Dividend paid	44,675	'	44,675	44,675	44,675	44,675	44,675	134,025	134,025	178,700	274,625
Preferred stock dividend in arrears	'	'	'	'	'	'	'	'	'	45,000	'
Period after which stock is redeemable at the option of the entity	'	'	'	'	'	'	'	'	'3 years	'	'
Preferred stock redemption price (in dollars per share)	'	'	'	'	'	'	'	'	$15	'	'
Preferred stock conversion ratio	'	'	'	'	'	'	'	'	1	'	'
Period after which stock can be converted at the option of the stockholders	'	'	'	'	'	'	'	'	'3 years	'	'
Number of shares of preferred stock converted into common stock	'	'	'	'	'	'	'	'	0	0	'
Amount per share the holders of the preferred stock entitled to in voluntary or involuntary dissolution, liquidation or winding up of the Company (in dollars per share)	'	'	'	'	'	'	'	'	$12.50	'	'
Number of consecutive quarters in which preferred stockholders have no voting right until dividends are in arrears	'	'	'	'	'	'	'	'	12	'	'
Right of preferred stock holders to elect a specified proportion of board of directors	'	'	'	'	'	'	'	'	0.33	'	'
Series III Class B Stock	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Preferred stock outstanding (in shares)	'	'	'	'	'	'	'	'	130,245	130,245	'
Cumulative annual dividend payable quarterly (in dollars per share)	'	'	'	'	'	'	'	'	$1	'	'
Preferred stock dividend in arrears	'	'	'	'	'	'	'	'	3,627,000	3,497,000	'
Period after which stock is redeemable at the option of the entity	'	'	'	'	'	'	'	'	'3 years	'	'
Preferred stock redemption price (in dollars per share)	'	'	'	'	'	'	'	'	$15	'	'
Preferred stock conversion ratio	'	'	'	'	'	'	'	'	1	'	'
Period after which stock can be converted at the option of the stockholders	'	'	'	'	'	'	'	'	'3 years	'	'
Number of shares of preferred stock converted into common stock	'	'	'	'	'	'	'	'	0	0	'
Amount per share the holders of the preferred stock entitled to in voluntary or involuntary dissolution, liquidation or winding up of the Company (in dollars per share)	'	'	'	'	'	'	'	'	$12.50	'	'
Series IV Class B Stock	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Preferred stock outstanding (in shares)	'	'	'	'	'	'	'	'	542,500	542,500	'
Cumulative annual dividend payable quarterly (in dollars per share)	'	'	'	'	'	'	'	'	$1	'	'
Preferred stock dividend in arrears	'	'	'	'	'	'	'	'	7,423,000	6,881,000	'
Period after which stock is redeemable at the option of the entity	'	'	'	'	'	'	'	'	'3 years	'	'
Preferred stock redemption price (in dollars per share)	'	'	'	'	'	'	'	'	$11	'	'
Preferred stock conversion ratio	'	'	'	'	'	'	'	'	1	'	'
Period after which stock can be converted at the option of the stockholders	'	'	'	'	'	'	'	'	'3 years	'	'
Number of shares of preferred stock converted into common stock	'	'	'	'	'	'	'	'	0	0	'
Amount per share the holders of the preferred stock entitled to in voluntary or involuntary dissolution, liquidation or winding up of the Company (in dollars per share)	'	'	'	'	'	'	'	'	$11	'	'
Series V Class B Stock	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	$1	'
Preferred stock outstanding (in shares)	'	'	'	'	'	'	'	'	40,000	46,607	'
Cumulative annual dividend payable quarterly (in dollars per share)	'	'	'	'	'	'	'	'	$0.32	'	'
Preferred stock dividend in arrears	'	'	'	'	'	'	'	'	$942,000	$929,000	'
Period after which stock is redeemable at the option of the entity	'	'	'	'	'	'	'	'	'2 years	'	'
Preferred stock redemption price (in dollars per share)	'	'	'	'	'	'	'	'	$4.40	'	'
Number of shares of preferred stock converted into common stock	'	'	'	'	'	'	'	'	6,607	0	'
Amount per share the holders of the preferred stock entitled to in voluntary or involuntary dissolution, liquidation or winding up of the Company (in dollars per share)	'	'	'	'	'	'	'	'	$4.40	'	'
Preferred Stock Class C	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Preferred stock authorized (in shares)	'	'	'	'	'	'	'	'	5,000,000	'	'
Preferred stock par value (in dollars per share)	'	'	'	'	'	'	'	'	$1	'	'
Common stock	'	'	'	'	'	'	'	'	'	'	'
STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'
Common stock authorized (in shares)	'	'	'	'	'	'	'	'	100,000,000	100,000,000	'
Common stock no par value (in dollars per share)	'	'	'	'	'	'	'	'	$0	$0	'
Common stock outstanding (in shares)	'	'	'	'	'	'	'	'	27,187,702	27,252,463	'
Number of shares repurchased	'	'	'	'	'	'	'	'	655,818	67,102	'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)	12 Months Ended						3 Months Ended		3 Months Ended
	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Nov. 04, 2011	Dec. 31, 2011	Dec. 31, 2011
		Series IV Class B	Series V Class B	Family members of Chief Executive Officer	Family members of Chief Executive Officer	Family members of Chief Executive Officer	Chief Executive Officer	Chief Executive Officer	Chief Executive Officer	Chief Executive Officer
									Series IV Class B	Series V Class B
RELATED PARTY TRANSACTIONS	'	'	'	'	'	'	'	'	'	'
Payment for various consulting services and participating in clinical trials	'	'	'	$93,939	$91,086	$96,787	'	'	'	'
Conversion of preferred stock into common stock (in shares)	1,277,464	10,000	1,185,964	'	'	'	86,607	'	'	'
Amount paid for conversion of preferred stock into common stock	1,357,275	35,000	1,138,525	'	'	'	95,843	'	'	'
Number of preferred stock shares exchanged against common stock and cash	1,277,464	10,000	1,185,964	'	'	'	'	'	5,000	81,607
Waiver of unpaid dividends in arrears	'	'	'	'	'	'	$58,110	'	'	'
Common stock closing stock price (in dollars per share)	'	'	'	'	'	'	'	$1.39	'	'

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (Stock Option, USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Jul. 10, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Maximum

Mr. Thomas J. Shaw

Mr. Thomas J. Shaw

Employee

Employee

Employee

Employee

Employee

Non-employee

Non-employee

Non-employee

1999 Stock Option Plan

2008 Stock Option Plan

Stock option grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option outstanding (in shares)

'

'

'

1,000,000

2,820,631

3,367,081

5,433,591

'

'

70,000

70,000

302,500

700

2,899,108

Options issued (in shares)

'

'

'

'

50,000

'

'

'

'

'

'

'

'

1,889,931

Shares of common stock authorized for exercise of options

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

Vesting period

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

Expiry term

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of employee options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at beginning of period (in shares)

'

'

'

1,000,000

3,367,081

5,433,591

5,508,513

'

'

70,000

302,500

302,500

700

'

Granted (in shares)

'

'

'

'

50,000

'

'

'

'

'

'

'

'

1,889,931

Exercised (in shares)

'

'

-2,000,000

'

-584,450

-2,000,865

-67,122

'

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

-12,000

-65,645

-7,800

'

'

'

-232,500

'

'

'

Outstanding at end of period (in shares)

'

'

'

1,000,000

2,820,631

3,367,081

5,433,591

'

'

70,000

70,000

302,500

700

2,899,108

Exercisable at end of period (in shares)

'

'

'

'

2,820,631

3,367,081

5,433,591

'

'

70,000

70,000

302,500

'

'

Weighted-Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at beginning of period (in dollars per share)

'

'

'

'

$0.95

$0.91

$0.91

'

'

$0.81

$5.49

$5.49

'

'

Granted (in dollars per share)

'

'

'

'

$1.46

'

'

$1.30

$0.81

'

'

'

'

'

Exercised (in dollars per share)

'

'

($0.81)

'

($0.92)

($0.81)

($0.81)

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

($2.38)

($2.29)

($0.85)

'

'

'

($6.90)

'

'

'

Outstanding at end of period (in dollars per share)

'

'

'

'

$0.95

$0.95

$0.91

'

'

$0.81

$0.81

$5.49

'

'

Exercisable at end of period (in dollars per share)

'

'

'

'

$0.95

$0.95

$0.91

'

'

$0.81

$0.81

$5.49

'

'

Options issued (in shares)

'

'

'

'

'

0

0

'

'

0

0

0

'

'

Weighted average fair value of options granted during period (in dollars per share)

'

'

'

'

$1.06

'

'

'

'

'

'

'

'

'

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Non-qualified stock option

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Employee

Non-employee

Non-employee

Non-employee

Non-employee

Non-employee

$8.87

$1.30

$1.46

$0.81

$0.81

Non-employee options outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Prices (in dollars per share)

'

'

'

$0.95

$0.95

$0.91

$0.91

$8.87

$1.30

$1.46

$0.81

$0.81

$0.81

$5.49

$5.49

$0.81

Shares Outstanding

'

'

'

'

'

'

'

700

754,103

50,000

2,015,828

'

'

'

'

70,000

Weighted Average Remaining Contractual Life

'

'

'

'

'

'

'

'4 months 10 days

'4 years 10 months 17 days

'9 years 4 months 13 days

'5 years 6 months 14 days

'

'

'

'

'5 years 6 months 14 days

Shares Exercisable

'

'

'

'

'

'

'

700

754,103

50,000

2,015,828

'

'

'

'

70,000

Fair value assumptions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility rate (as a percent)

'

'

'

67.53%

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate (as a percent)

'

'

'

3.35%

'

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'

'8 years 7 months 10 days

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

$52,775

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intrinsic value of options exercised

1,210,135

220,268

49,626

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding and exercisable

6,158,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested stock options

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401k_PLAN_Details

401(k) PLAN (Details)	12 Months Ended
	Dec. 31, 2013
401(k) PLAN	'
Maximum percentage of compensation that employees may elect to contribute	88.00%

BUSINESS_SEGMENTS_Details

BUSINESS SEGMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales by geographical areas	'	'	'
Total sales	$30,785,127	$33,644,503	$32,102,296
U.S.	'	'	'
Sales by geographical areas	'	'	'
Total sales	24,843,200	25,363,814	26,655,781
Long-lived assets	'	'	'
Long-lived assets	10,676,053	11,679,592	12,412,502
North and South America sales (excluding U.S.)	'	'	'
Sales by geographical areas	'	'	'
Total sales	4,453,151	4,668,550	4,736,356
Other international sales	'	'	'
Sales by geographical areas	'	'	'
Total sales	1,488,776	3,612,139	710,159
International	'	'	'
Long-lived assets	'	'	'
Long-lived assets	$234,119	$220,058	$241,354

Schedule_IISchedule_of_Valuati1

Schedule II-Schedule of Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Provision for Inventories	'	'	'
Movement in schedule of valuation and qualifying accounts	'	'	'
Balance at beginning of period	$239,752	$258,435	$205,600
Additions	530,000	120,000	52,835
Deductions	88,357	138,683	'
Balance at end of period	681,395	239,752	258,435
Provision for Rebates	681,395	239,752	258,435
Provision for Accounts Receivables	'	'	'
Movement in schedule of valuation and qualifying accounts	'	'	'
Balance at beginning of period	2,186,190	2,078,944	780,900
Additions	50,000	107,246	1,298,044
Deductions	537,684	'	'
Balance at end of period	1,698,506	2,186,190	2,078,944
Provision for Rebates	1,698,506	2,186,190	2,078,944
Deferred Tax Valuation	'	'	'
Movement in schedule of valuation and qualifying accounts	'	'	'
Balance at beginning of period	6,039,054	4,883,416	5,442,682
Additions	2,404,763	1,155,638	'
Deductions	'	'	559,266
Balance at end of period	8,443,817	6,039,054	4,883,416
Provision for Rebates	8,443,817	6,039,054	4,883,416
Provision for Rebates	'	'	'
Movement in schedule of valuation and qualifying accounts	'	'	'
Balance at beginning of period	21,993,267	16,158,795	11,102,329
Additions	17,912,447	19,615,388	19,229,308
Deductions	13,112,048	13,780,916	14,172,842
Balance at end of period	26,793,666	21,993,267	16,158,795
Provision for Rebates	26,793,666	21,993,267	16,158,795
Accounts payable	'	'	'
Movement in schedule of valuation and qualifying accounts	'	'	'
Balance at end of period	3,611,962	3,036,564	2,170,764
Provision for Rebates	$3,611,962	$3,036,564	$2,170,764